Abstracts by Polskiego Towarzystwa Neuroendokrynologii, IV Zjazd



	


	 ­
	

	



  
 



   
 
  
 		
 	
 	
 			



 
¡  

	
¡	¢	£
¤¥	¦



	 ­§¦¨©¨©


	
 

	
 
		
	

 
					
 
	


 		
 	


	 ­
 ­
 	
417
Abstracts 
M
A
T
ER
IA
ŁY
 Z
JA
Z
D
O
W
E
The diagnostic significance of copeptin
Bogusława Baranowska1, Wojciech Bik2, Jan Kochanowski1
1Neurology Department, Medical University, Warsaw
2Neuroendocrinology Department, Medical Center of Postgraduate Education, 
Warsaw
Introduction: Copeptin is a 39 aminoacid peptide that shares pre-
cursor preprovasopressin, both with vasopressin and neurophysin 
II. The evaluatio0n of copeptin is useful in the differential diagnosis 
of polydipsia — polyuria syndrome. Copeptin is also a good diag-
nostic and prognostic marker in myocardial infarction, heart failure, 
myocarditis, degenerative aortic stenosis, ischemic cerebral stroke, 
subarachnoid hemorrhage, sepsis, metabolic syndrome, diabetes with 
albuminuria. Besides antidiuretic effects, copeptin stimulates ACTH 
secretion. The activation of the hypothalamo-pituitary-adrenal axis is 
the early response of cerebral ischemic stroke and also it may influence 
the intensity of immunological processes in multiplex sclerosis (MS). 
Material and methods: The aim of this study is to evaluate plasma 
copeptin concentrations in 150 patients with acute ischemic stroke 
and 29 with multiple sclerosis, in comparison to control groups. 
Results: In the patients with acute ischemic stroke plasma copeptin 
levels were significantly higher (p < 0.001) as compared with the 
controls. The correlations of copeptin with metabolic markers and 
severity of stroke (NIHSS) scale were evaluated. In the patients with 
MS plasma copeptin levels were higher compared to the control 
group but the difference was not significant. However, the values of 
copeptin in overweight/obese patients with MS were significantly 
higher than those found in overweight/obese and lean subjects 
of the control group (p < 0.05, p < 0.01) and lean MS (p < 0.05). 
The correlations between copeptin and metabolic markers were 
investigated.
Conclusions: Copeptin is a potential prognostic marker in acute 
ischemic stroke. Elevated copeptin levels in patients with MS may 
be partly connected with obesity and some components of meta-
bolic syndrome. 
Grant CMKP 501-1-31-22-14.
Neuroendocrine and metabolic aspects of selected 
central nervous system diseases
Agnieszka Baranowska-Bik1, Wojciech Bik2,  
Maria Barcikowska3, Jan Kochanowski4,  
Bogusława Baranowska4 
1Department of Endocrinology Centre of Postgraduate Medical Education Warsaw, Poland
2Department of Neuroendocrinology Centre of Postgraduate Medical Education 
Warsaw, Poland
3Department of Neurodegenerative Disorders, Medical Research Centre, Polish 
Academy of Science Warsaw, Poland
4Department of Neurology; Second Faculty of Medicine, Medical University 
Warsaw, Poland 
Introduction: An ageing society results in the growing incidence 
of dementia and cardiovascular diseases. Several studies indi-
cate an essential role of obesity and obesity-related metabolic 
disturbances, including insulin resistance, in the etiology of the 
above mentioned diseases. Adipokines, peptides produced by the 
adipose tissue, may play an important role in the pathogenesis 
of dementia and ischemic stroke. Adipokines possess pleiotropic 
properties, including the immunomodulation and modification 
of insulin sensitivity.
To assess the concentration of selected adipokines (adiponectin 
and its fractions, leptin and soluble leptin receptor, resistin) and 
insulin-resistance parameters in Alzheimer’s disease (AD) and in 
individuals with a newly diagnosed brain ischemic stroke.
Material and methods: A group of AD patients consisted of 58 
women. A control group comprised of 42 non-demented women 
matched for age and BMI. 150 women were amongst ischemic stroke 
patients. A control group consisted of 75 women matched for age 
and BMI. Selected adipokines and insulin-resistance parameters 
were measured once in dementia individuals and those results 
were correlated with dementia index (MMSE). In the women with 
ischemic stroke the measurements of adipokines were performed 
twice, on the 1st and 10th day. The results were correlated with stroke 
severity index (NIHSS). 
Results: Among the women with AD we noticed the decreased lev-
els of leptin and the increase in soluble leptin receptor concentration 
as well as in adiponectin levels in comparison with the results of 
the controls. In the women with brain ischemic stroke we found 
an altered adipokine profile (higher levels of leptin and resistin, 
the decreased concentrations of adiponectin and soluble leptin 
receptor), remaining in the 10th day of the stroke. The correlation 
between NIHSS and total adiponectin, HMW adiponectin and 
resistin was observed.
Conclusions: Alterations in adipokine concentrations in the 
presented diseases of the central nervous system may reflect the 
intensity of metabolic disturbances in the course of those disorders. 
The study was supported by grants: MNiSW 2794/B/P01/2009/36; 
MNiSW 5484/B/P01/2011/40
Alzheimer’s disease — challenge of 21-st century
Maria Barcikowska 
Department of Neurodegenerative Disorders, Medical Research Centre, PAS, 
Warsaw, Poland
The development of basic research in the field of neurodegenerative 
diseases resulted in the need of a radical revaluation of methods 
of diagnosis, which also includes Alzheimer’s disease (AD). The 
results of neuropathological tests indicated that in case of AD 
the presymptomatic stage can last even 20 years. The process of 
Alzheimer’s type brain degeneration, which is the accumulation 
of toxic forms of amyloid beta (Ab) and the release of phospho-tau 
and also total tau protein from the damaged neutrons, starts long 
before the critical number of neutrons is damaged. This has been 
officially accepted in the NIA/AA criteria for AD diagnosis (2011), 
which establish the rules for recognizing AD while still in the 
Redakcja „Endokrynologii Polskiej” nie ponosi odpowiedzialności za treść streszczeń.
Streszczenia
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preclinical stage. This phase is crucial for treatment that can slow 
down the pathological process before the irreversible brain dam-
age occurs. Clinically, during this phase of the disease a patient 
shows only slight symptoms of the ongoing process which can 
be recognized only using highly sophisticated examination. The 
clinical tests of medications that can be used in this stage of AD 
are currently already carried out. They are aimed at the population 
of persons who are the carriers of the gene mutations (APP and 
two presenilins) that are causative agents for AD. The so called 
sporadic cases in which the genetic background of the disease has 
still not been defined despite the ongoing GWAS examination will 
not be routinely diagnosed and treated in the preclinical phase for 
a long time. Apart from the genetic research aimed at diagnosing 
AD also biochemical biomarkers (Ab, phospho- and total tau CSF 
concentration) are widely used to diagnose the already ongoing 
pathological degeneration of Alzheimer’s type, as well as more 
and more sophisticated methods of neuroimaging, such as using 
PIB in the PET as a marker of the presence of Ab in the living brain.
Macroprolactine detection with precipitation method 
— the evaluation of different technical variants
Karolina Beda-Maluga, Aleksandra Adamusiak,  
Hanna Pisarek, Jacek Świętosławski, Katarzyna Winczyk
Department of Neuroendocrinology, Chair of Laboratory Diagnostics, Medical 
University of Lodz
Introduction: Macroprolactin (MaPRL) is a large-molecule form 
of prolactin (PRL). It has limited biological activity but reacts with 
immunotests for PRL measurement and, therefore, in about 20% 
of cases may be the cause of the elevated hormone level. To detect 
macroforms, precipitation with polyethylene glycol (PEG) is used. 
This method involves the incubation and centrifugation of serum 
with PEG, then the measurement of PRL in supernatant and the 
evaluation of real PRL concentration or calculating the percent 
recovery of hormone. The parameters of centrifugation described 
in literature differ significantly. For this reason the aim of the study 
was to assess whether reducing the time and increasing the speed 
of rotation, allowing the quicker obtainment of the result, affects 
the amount of precipitate MaPRL, and, thus, the value of real PRL 
concentration and hormone recovery.
Material and methods: The study involved 56 sera obtained from 
patients treated in the Department of Endocrinology, Medical 
University of Lodz. Prolactin was measured with the use of en-
zyme-amplified chemiluminescent method (EACLIA) on the analyz-
er Immulite 1000 (Siemens). The sera, depending on the native PRL 
concentration were classified into the following groups: group 1: 10 
sera with normal PRL level, group 2: 34 sera with hyperprolactinae-
mia below 100 ng/mL, group 3: 12 sera with hyperprolactinaemia 
above 100 ng/mL. Each serum was mixed with PEG, incubated and 
centrifuged according to the three options: variant I: 3000 rpm/30 
min., variant II: 6000 rpm/8 min., variant III: 9000 rpm/4 min. In 
the obtained supernatants the PRL was measured and then, the 
concentrations of the real PRL concentration (hormone level after 
precipitation) were assessed as well as recovery values calculated 
by comparing the concentration of the hormone before and after 
precipitation. 
Results: Average differences between the real PRL concentrations 
obtained with the use of the different variants of centrifugation were 
in: group 1 — 0.65 ng/mL, group 2 — 1.30 ng/mL, and in group 3 — 
16.54 ng/mL. In turn, the recovery values of the hormone differed 
by an average of 3.18% in group 1, 2.76% in group 2 and 4.23% in 
group 3. The analysis showed that in all the groups the obtained 
differences are statistically significant, but the majority of them 
(87%) is within the error of the EACLIA method. 
Conclusions: Modification of the parameters of centrifugation, 
such as speed and time, affect the amount of precipitated PRL 
macroforms, and, therefore, the value of the real concentration of 
the hormone and the percentage recovery. The differences between 
the values obtained in three PRL variants of rotation are statistically 
significant, but small differences do not affect the clinical interpreta-
tion of the results. The shortening of the time of precipitation using 
the appropriate speed lets obtain the similar, from a clinical point 
of view, efficiency of precipitation for each of the tested variants.
This study was supported by grant no 503/5-020-02/503-01.
Evaluation of pituitary function in patients  
with macroprolactinoma treated surgically
Karolina Beda-Maluga, Justyna Janocha, Hanna Pisarek, 
Julita Fuss-Chmielewska, Katarzyna Winczyk
Department of Neuroendocrinology, Chair of Laboratory Diagnostics, Medical 
University of Lodz 
Introduction: The first-line treatment of prolactinoma is pharmaco-
therapy with dopamine agonists. However, in patients with poor 
tolerance, drug resistance or in case of a giant adenoma surgery 
is performed. The outcomes of surgical treatment are dependent 
mainly on the size of the tumour as well as on the experience of the 
surgeon. The aim of this study was to evaluate the pituitary function 
in patients after prolactinoma surgery both in terms of the treatment 
effectiveness and complications due to the surgical procedure. 
Material and methods: A study group consisted of 27 patients (11 
women and 16 men, aged 22–69 years) after macroprolactinoma sur-
gery that had control test in the Clinic of Endocrinology, Medical 
University of Lodz. As the biochemical marker of cure, we assumed 
the normalization of PRL level — that means hormone concentration 
within reference range. We also evaluated the concentrations of other 
pituitary hormones and the hormones secreted by peripheral glands.
Results: The normalization of PRL concentration was achieved in 
20/27 (74%) patients — a correct pituitary function was restored in five 
of them, hypopituitarism was noted in 15 persons. In seven subjects 
PRL level after the surgery was still elevated (two patients with proper 
pituitary function, five persons with hypopituitarism). Transsphenoi-
dal surgery was performed in 12 patients - the normalization of PRL 
level was achieved in ten of them, an incorrect pituitary function was 
observed in nine. In all the persons after craniotomy hypopituitarism 
occurred and normal PRL level was achieved in half of them. 
Conclusions: The surgical resection of macroprolactinoma leads to 
the normalization of PRL in almost 3/4 of patients. Hypopituitarism 
incidence after surgery is high — occurs in, approximately, 70% 
of persons. Transsphenoidal operation is associated with a lower 
risk of hypopituitarism than transcranial resection of the tumour.
Evaluation of pituitary function in patients  
with corticotropinoma treated surgically
Karolina Beda-Maluga, Ewelina Ślusarczyk,  
Hanna Pisarek, Julita Fuss-Chmielewska,  
Katarzyna Winczyk
Department of Neuroendocrinology, Chair of Laboratory Diagnostics, Medical 
University of Lodz
Introduction: In patients with Cushing’s disease caused by corticotro-
pinoma the treatment of choice is the surgical removal of the adenoma 
with an access via the sphenoid sinus. The aim of the study was to 
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evaluate the pituitary function in patients after corticotropinoma re-
section both in terms of efficacy and complications after the surgery.
Material and methods: The study group consisted of 21 patients 
(16 women and 5 men aged 28-68 years) operated due to corticotro-
pinoma and, in order to perform control tests, hospitalized in the 
Department of Endocrinology, Medical University of Lodz. The 
effectiveness of neurosurgical treatment was assessed on the basis 
of morning concentrations of ACTH and cortisol, circadian secretion 
of these hormones and/or dexamethasone suppression test results. 
Postoperative pituitary hormonal function was assessed on the 
basis of concentrations of hormones secreted by the pituitary and 
peripheral endocrine glands.
Results: The majority of the operated patients (18/21) had microade-
noma. The cure of Cushing’s disease was achieved in 15/21 patients 
(71%) — in 4 of them (including two after reoperation) postoperative 
hypopituitarism was noted. In 6 patients (29%) the neurosurgical 
procedure did not lead to the normalization of cortisol levels — 
only one of these persons (after reoperation) had hypopituitarism.
Conclusions: The surgical resection of corticotropinoma is an effective 
method of Cushing’s disease treatment and quite rarely — usually 
after reoperation — leads to hypopituitarism.
Advances in diagnostics and therapy of acromegaly
Marek Bolanowski
Department of Endocrinology, Diabetes and Isotope Therapy, Medical University 
Wrocław
Significant advances in the diagnostics and therapy of acromegaly 
have been noticed recently. There are reports on the administra-
tion of new formulations (octreotide implant and oral form), a new 
analogue (pasireotide) in the direct comparison to octreotide, and 
the efficacy of first-line lanreotide medical therapy regarding tu-
mour volume decrease and hormonal normalization (clinical study 
PRIMARYS). Current guidelines (Polish and international) were 
published. They focus on severe acromegaly complications and 
the precise rules of the management of patients. IGF-1 concentra-
tion is crucial for screening and monitoring of the diseases course.
Neuroendocrine responses to opioid receptor 
blockade during repeated forced exercise in pigs 
with mutated ryanodine receptor gene
Ziemowit Ciepielewski, Wojciech Stojek,  
Dorota Myślińska, Edyta Jurkowlaniec-Kopeć
Department of Animal and Human Physiology, Faculty of Biology, University of 
Gdansk, Gdansk, Poland
Introduction and Aim: The aim of the study was to determine 
the role of the opioid receptor system during rest and exercise in 
pigs with a mutation in the ryanodine receptor gene (RYR1). In the 
present study, in 60 catheterized male pigs (Polish synthetic line 990), 
the relation of the mutation in RYR1 gene with the neuroendocrine 
responses during the repeated exercise (forced walking, FW) was 
investigated after the opioid receptor blockade with non-specific 
antagonist naloxone (NX, 1 mg/kg BW).
Methods: The pigs were divided (molecular assay screening 
mutation of the RYR1 gene) into three groups: stress susceptible 
homozygotes-nn; and stress-resistant: heterozygotes-Nn and ho-
mozygotes-NN were subjected to FW twice (20-min, with an hour rest 
between FWs) in the treadmill. Plasma concentrations of adrenaline 
(A), noradrenaline (NA), (HPLC) and prolactin (PRL), growth hormone 
(GH), beta-endorphin (BEND), adrenocorticotropin (ACTH) and 
cortisol (COR) (RIA) were measured in the presence or absence of NX.
Results: It was found that FW alone increased (p < 0.05) plasma 
concentrations of all the measured hormones and the effects were 
dependent on the genotype of the pig. The greatest concentrations 
of A, PRL and BEND were observed in nn homozygous pigs, and 
the greatest concentration of NA and GH in NN homozygous pigs. 
Plasma ACTH and COR did not differ between RYR1 genotypes. 
Moreover, the increases in PRL and GH were observed only after 
the first FW. During FW preceded with NX the increases in plasma 
concentrations of A, PRL, BEND were diminished (p < 0.05), in 
all three genotypes and plasma GH and ACTH were augmented 
(p < 0.05) as compared to the pigs exercised without NX. The 
NX-induced diminishing effects were more pronounced in nn 
pigs and augmenting effects in NN pigs.
Conclusion: The results support a regulatory effect of the opioid 
receptor system activation on neuroendocrine responses during 
exercise and the intensification of the opioid activation may depend 
on RYR1 gene status.
Galanin-like peptide modifies feeding behavior, 
water intake and the hypothalamo-neurohypophysial 
system function of Wistar rats
Joanna Ciosek
Department of Neuropeptides Research, Chair of General and Experimental Patho-
logy, Medical University of Lodz, Poland
Introduction: Galanin-like peptide (GALP), being an important 
member of galanin neuropeptides family, is present in some 
areas of the central nervous system. GALP may be involved in 
the mechanisms controlling some processes connected to energy 
metabolism. Some previous findings indicate the ability of GALP 
to alter vasopressin (AVP) and oxytocin (OT) secretion from the 
posterior pituitary gland. 
Aim of the study: This experiment was performed to study the 
effects of GALP, injected intravenously (iv), on food and water 
intake as well as body weight changes of experimental animals; 
AVP and OT release from the neurohypophysis (NH) into blood 
was also estimated. 
Material and methods: Male adult Wistar rats were divided into 
two series: series A — rats injected iv with 0.9% NaCl; series B — rats 
injected iv with GALP in a dose of 50 ng/100 g b.w. The appropriate 
solutions were administered twice a day: in the morning (8.30–9.00 
a.m.) and in the evening (5.30–6.00 p.m.); the number of injections: 
group I, II and III — 3, 5 or 7, respectively. AVP and OT content in 
the hypothalamus, neurohypophysis and the blood were estimated 
by radioimmunoassay.
Results: GALP was the reason of distinctly increased water and 
food intake as well as body weight of the experimental animals. In 
all the groups the tendency to impair AVP and OT release into the 
blood connected with the increase of both neurohormones content 
in the neurohypophysis has been observed.
Conclusions: It may be assumed that GALP, injected intravenous-
ly, modifies such systemic mechanisms which are engaged in the 
changes of energy metabolism. Simultaneously, GALP plays the role 
of inhibitory neuromodulator of AVP and OT release. 
This study was supported by grant of Medical University of Lodz 
no 503/6-103-02/503-01.
Melatonin exerts regulatory effect on oxytocin 
release in rats with myocardial infarction
Joanna Ciosek, Anna Krzymińska, Jacek Drobnik
Department of Neuropeptides Research, Chair of General and Experimental Patho-
logy, Medical University of Lodz, Poland
420
Abstracts	
M
A
T
ER
IA
ŁY
 Z
JA
Z
D
O
W
E
Introduction: The increased secretion of both vasopressin (AVP) 
and oxytocin (OT) is frequently observed in subjects with heart 
failure. The pineal gland and melatonin regulatory effect on the 
hypothalamo-neurohypophysial system has been reported. 
The present study is aimed at verifying whether melatonin (MLT) 
exerts a regulatory effect on the secretion of oxytocin from the 
hypothalamo-neurohypophysial system in rats with myocardial 
infarction (MI).
Material and Methods: Myocardial infarction was induced by the 
ligation of the left coronary artery. OT content was radioimmunoa-
sayed in control groups, rats treated with vehicle (2% ethanol solu-
tion in 0.9% NaCl), MLT injected animals (60 µg/100 g body weight), 
sham-operated or pinealectomized rats as well as pinealectomized 
rats treated with vehicle or melatonin. 
Results: Elevated OT level in the serum of rats with MI was linked 
with the lower content of this hormone in the hypothalamus and 
neurohypohysis. MLT decreased concentration of OT in the serum 
but both in the hypothalamus and neurohypophysis content of this 
neurohormone was elevated. Contrary to melatonin, pinealectomy 
increases OT level in blood plasma and decreases the content of 
this hormone in the neurohypohysis. The application of MLT to the 
pinealectomized rats results in the lowering of OT concentration 
in blood plasma and increases this neurohormone content in the 
neurohypophysis and hypothalamus.
Conclusions: Melatonin inhibits the release of oxytocin from the 
neurohypophysis and decreases the concentration of this hormone 
in the serum of rats with myocardial infarction. The results of this 
study show that melatonin turns away the effect of myocardial 
infarction and restricts the increased oxytocin release.
This study was supported by grant of Medical University of Lodz 
no 503/6-103-02/503-01.
Neurohormonal changes after surgical treatment  
for obesity
Michał Dyaczyński1, Grzegorz Kowalski1,  
Krystyna Pierzchała-Koziec2, Joanna Zubel2, Ewa Ocłoń2, 
Anna Latacz2, Klaudia Pałka2
1Department of General Surgery, Subdepartment of Metabolic and Bariatric 
Surgery, District Railway Hospital, Katowice, Poland
2University of Agriculture, Krakow, Poland
Introduction: The effectiveness of surgical treatment for obesity is 
much higher than standard methods. However, surgery has side 
effects by itself and also the postbariatric convalescence affects the 
activity of the hypothalamo-intestinal axis. Clinical investigations 
showed serious changes of nervous, immune and endocrine systems 
in patients after the surgery. 
The aim of the experiment was to estimate the changes of neuro-
transmitters and hormones in animal models (pigs and rats) after 
bariatric surgery. Additionally, the effects of synbiotics supplemen-
tation were tested in these animals. 
Material and methods: Two weeks (pigs) or four weeks (rats) after 
bariatric surgery blood and fragments of tissues-duodenum, stom-
ach, jejunum, pancreas and brain-were taken. The concentration, 
secretion and synthesis of Met-encephalin (neurotransmitter) were 
estimated by RIA method. Also, the levels of ghrelin, insulin, gluca-
gon and the lipid and glycemic profiles were measured. 
Results: The results clearly showed the changes in the synthesis 
and secretion of Met-encephalin in the gastrointestinal and brain 
fragments. The levels of all the tested parameters were significant-
ly changed by the bariatric procedures. Synbiotic modulated the 
hormonal and biochemical changes.
Conclusion: Bariatric surgery has a long term impact on the activity 
of hypothalamo-intestinal axis, particularly on the neurohormonal 
parameters.
Supported by Grant NCBiR 12006406, DS3243/KFiEZ
Review of fractionated radiotherapy and stereotactic 
radiosurgery for medically and surgically refractory 
pituitary adenomas
Jacek Fijuth
Department of Radiotherapy, Chair of Oncology, Medical University of Lodz 
Pituitary adenomas are relatively common tumors, comprising 
approximately 10-20% of all primary intracranial lesions, with 
a reported incidence of up to 20% within the general population. 
For decades, radiation therapy has served as an adjuvant treat-
ment for residual or recurrent pituitary adenomas or as a primary 
treatment in patients who are not candidates for surgery. While 
surgical intervention remains the first-line therapy, stereotactic 
radiosurgery is increasingly recognized as a viable treatment option 
for these often challenging tumors. Despite advances in surgical 
techniques and medical therapies, a significant proportion of pitu-
itary adenomas remain hormonally active, demonstrate persistent 
radiographic disease, or recur when followed for long periods of 
time. Stereotactic radiosurgery (SRS) has recently received a great 
deal of attention in the secondary treatment of pituitary adenomas. 
The ability to deliver the full treatment dose within one session, and 
the theoretically reduced risk of injury to nearby neural structures 
on account of the conformal nature of the beams gained SRS im-
mediate popularity. The hormonal remission rates vary by tumor 
type: from 20-30% in prolactinoma, ~50% in growth hormone 
secreting adenomas, to 40-65% in adrenocorticotrophic hormone 
(ACTH)-secreting adenomas. The time to remission radiographic 
control rates is almost universally greater than 90% with long-term 
follow-up. However, given the relative novelty of SRS compared to 
conventional radiotherapy, long-term studies on the efficacy and 
complications of SRS are still being acquired. The authors stratify 
the outcomes by tumor type, review the importance of prognostic 
factors (particularly, pre-treatment endocrinologic function and 
tumor size), and discuss the complications of treatment with special 
attention to endocrinopathy and visual complications. The authors 
conclude that the literature supports the use of radiosurgery for 
treatment-refractory pituitary adenomas, providing the patient 
with a minimally invasive, safe, and effective treatment option 
for an otherwise resistant tumor. The authors present their own 
experience and provide literature-based treatment considerations, 
including radiosurgical dose, endocrinologic, radiographic, and 
medical considerations for each adenoma type.
New aspects of Parkinson’s disease
Urszula Fiszer1, Małgorzata Michałowska1,  
Bogusława Baranowska2
1Department of Neurology and Epileptology, Medical Centre of Postgraduate 
Education, Warsaw
2Department of Endocrinology, Medical Centre of Postgraduate Education, 
Warsaw
Introduction: Parkinson’s disease (PD) is a progressive multisystem 
disorder that includes motor and non-motor symptoms. Recently, 
several PD subtypes have been identified but the pathogenic mech-
anisms underlying the observed clinicopathologic heterogeneity in 
PD are still not well understood. Inflammation bas been proposed 
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as one of the factors contributing to the onset and progression of 
neuronal death in PD. Studies have shown that PD patients present 
lower body weights in comparison with age-matched subjects. The 
mechanism underlying the weight loss in PD is unknown.
To investigate the role of leptin, ghrelin, GH and IGF-1 in energy 
balance disturbances in Parkinson’s disease (PD). Adipokines are 
of great interest since they are involved in inflammation and other 
physiological processes.
Materials and methods: The study included 39 patients: 11 PD 
patients with unintentional weight loss, 16 PD patients without 
weight loss and 12 controls. UPDRS, MMSE, MADRS, appetite 
scale, BMI, adipose tissue content, plasma leptin and active ghrelin 
concentrations and serum GH, IGF-1, TSH, T3 and T4 concentrations 
were evaluated.
Results: A lower plasma leptin concentration and a higher serum 
IGF-1 concentration were found in PD patients with weight loss. 
BMI and the content of adipose tissue were positively correlated 
with leptin concentration in all PD patients. However, the lower 
BMI was, the lower plasma active ghrelin concentration was in PD 
patients with weight loss.
Conclusion: These findings confirm that the changes of plasma 
leptin concentration occur in PD patients with the loss of weight.
This work was supported by Medical Centre of Postgraduate Edu-
cation in Warsaw (grant no. 501-1-1-13-5428-05).
Biochemical evaluation of treatment effectiveness in 
patients with acromegaly
Julita Fuss-Chmielewska, Aleksandra Rosiak, Hanna Pisarek, 
Karolina Beda-Maluga, Katarzyna Winczyk
Department of Neuroendocrinology, Chair of Laboratory Diagnostics, Medical 
University of Lodz
Introduction: In patients with somatotropinoma the surgical removal 
of the tumour is routinely performed. Pharmacotherapy, usually 
with somatostatin analogues (SSA), is used as the preliminary and/
or complementary therapy. In cases of ineffective surgical and 
pharmacological treatment, though less frequently, radiotherapy 
is applied. The aim of this study was to evaluate the concentration 
of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) 
— biochemical parameters of acromegaly treatment efficacy. 
Material and methods: The study group consisted of patients 
after the removal of the pituitary somatotropinoma — 27 women 
and 13 men aged 25 to 83 years — hospitalized in the Clinic of 
Endocrinology, Medical University of Lodz. The concentrations 
of GH and IGF-1 in blood serum were determined with the use 
of the immunochemical analyzer IMMULITE 1000 (Siemens). As 
the criteria of acromegaly cure, we assumed the normalization of 
serum IGF-1 concentration and GH level after the administration 
of glucose (OGTT) less than 1 ng/mL. 
Results: In the study group, 25 of 40 patients (63%) fulfilled the 
cure criteria. In 14 patients, the normalization of IGF-1 and GH 
were obtained as a result of neurosurgery only, 11 patients achieved 
normal laboratory parameters after surgery and additional treat-
ment — including five after the SSA administration, four after radi-
otherapy, and two after pharmaco- and radiotherapy together. The 
normalization of GH and/or IGF-1 was not observed in 15 operated 
patients: 13 were treated with SSA after the operation and four of 
them also before the surgery. The group of 21 patients was treated 
with SSA before surgery and among them only five were not cured.
Conclusions: In most patients with acromegaly after neurosurgical 
resection of the pituitary adenoma the complementary therapy 
— mainly pharmacological — is needed. The preoperative ad-
ministration of somatostatin analogues significantly increases the 
effectiveness of the treatment.
Regulatory role OF Wnt/Β-catenin and BMPs 
signaling in gonadotropin network genes expression 
Alina Gajewska, Marlena Zielińska-Górska
The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of 
Sciences, Jablonna n. Warsaw
Upon binding to its G-protein coupled receptor, gonadoliberin 
(GnRH) induces a signal which then flows through MAPK cascades 
leading to the phosphorylation of a number of downstream targets 
including several DNA-binding proteins and the regulation of go-
nadotropin gene transcription and secretion. The effort to identify 
the full spectrum of signal transduction pathways targeted by the 
type I GnRHR revealed a crucial role of Wnt/β-catenin transduction 
in gonadotrope cells. β-catenin is a transcriptional coactivator as-
sociated with T cell factor/Lymphoid enhancer factor — responsive 
genes regulated by the WNT family of secreted glycoproteins. The 
dependence of Wnt/β-catenin signaling on GnRHR activation was 
shown in the studies on gonadotroph-derived LβT2 cell line ac-
cording to GnRH-stimulated nuclear localization of β-catenin and 
parallel increases in GnRH-dependent mRNAs specific for Jun, 
Fra1 and Myc. Wnt/β-catenin signaling regulates steroidogenic 
transcription factor (SF-1) gene activity. SF-1 response elements 
are found in the promoter regions of four gonadotrope signature 
genes: LHβ, FSHβ α-GSU and GnRH-R. β-catenin and Dax-1 act as 
SF-1 transcriptional coactivator/repressor, respectively, to affect SF-1 
mediated transcription of its target genes. The studies on LβT2 cells 
also evidenced that locally produced bone morphogenetic proteins 
(BMPs) form a signaling system that acts as a major functional regu-
lator of pituitary cells function. Accumulating evidence indicates 
that BMPs operate through Smad-independent pathways such as 
MAPK signaling molecules and convergent effects of independent 
pathways elicited by BMPs/activin and GnRH are likely linked to 
the combined response leading to the effective amplification of 
FSHβ transcription. Our in vivo studies revealed that the central 
and steroidal modulation of endogenous GnRH neurons activity 
had an impact on Wnt/βcatenin and BMPs signaling pathways 
and these effects were exerted at specific SF-1/βcatenin/Dax-1 and 
selected BMPs genes transcriptional level.
cAMP/PKA pathway signaling in the anterior pituitary 
cells in vitro: intracellular mechanisms of Cu-GnRH 
complex activity
Alina Gajewska1, Marlena Zielińska-Górska1,  
Ewa Wolinska-Witort2, Marta Baran1, Grzegorz Kotarba2, 
Kazimierz Kochman1
1The Kielanowski Institute of Animal Physiology and Nutrition, PAS, Jablonna  
n. Warsaw
2Medical Centre of Postgraduate Education, Warsaw
Introduction: Complex Cu-GnRH is a gonadoliberin analog which 
preserves an amino acid sequence identical like in native decapep-
tide but contains Cu2+ ion bound to the histidine (His2). In previous 
studies we found that Cu-GnRH stimulates gonadotropin release 
more potently, exhibits the reduced susceptibility to proteolytic 
cleavage and is able to activate cAMP/PKA signaling in the anterior 
pituitary cells.
The determination whether specific receptors (GnRHR and/or 
PAC-1) and protein kinases C and/or A are involved in Cu-GnRH-
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induced cAMP accumulation. The evaluation of Cu-GnRH effect on 
selected gonadotrophic network genes mRNA expression.
Material and Methods: 5 × 105/mL anterior pituitary cells were 
incubated (37°C) for 0.5–1–3 h in DMEM with 10–7M Cu-GnRH with/
without GnRHR antagonists (antide, cetrorelix), PAC-1 receptor 
(PACAP6–38), PKA (H89, KT 5720) and PKC (GF 109203X) inhibitors, 
Ca2+-selective ionophore A23187 and cycloheximide. Intracellular 
cAMP level and LH medium concentration were determined by 
RIA. 60 anterior pituitary glands from diestrus females were incu-
bated for 2 and 5 h (37°C) in M199 medium with 10–6M Cu-GnRH 
in the presence of KT 5720. Egr-1, LHβ, GnRHR PAC-1 and NOS1 
mRNA expression were analyzed by qRT-PCR method.
Results: Cu-GnRH-induced cAMP accumulation was dependent 
on GnRHR as well as PAC-1 receptors activation. Although de novo 
protein synthesis was not required, an intracellular, Ca2+ and Ca2+/
calmodulin-dependent adenylate cyclase might be involved in 
this process. Complex activity was mediated by PKA however, no 
impact of PKC was found. PKA activation inhibited mRNA expres-
sion of two crucial gonadotropic network genes: Egr-1 and LHβ. A 
pro-gonadotropic Cu-GnRH effect was exerted via stimulation of 
GnRHR and NOS-1 mRNA expression.
Conclusions: Cu-GnRH conformation enables the interaction 
with GnRHR and PAC-1 receptors. Complex-induced cAMP/PKA 
signaling is involved in gene-specific impact exerted by Cu-GnRH 
on gonadotrophic network transcriptional activity.
Supported by grant KBN: N N311 406739
Oxytocin receptor gene expression in anterior 
pituitary of lactating ewe in the aspect of prolactin 
secretion regulation
Konrad Górski, Elżbieta Marciniak, Małgorzata Hasiec, 
Tomasz Misztal 
The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy  
of Sciences, Jablonna n. Warsaw
Introduction: Prolactin (PRL) secretion is regulated by the complex 
network of hormones and neurotransmitters. Numerous data indi-
cate that one of them is oxytocin (OT) which shows stimulating ac-
tion on the PRL secretion. Furthermore, in rat anterior pituitary (AP) 
the expression of oxytocin receptor (OTR) occurs and this expression 
increases during lactation. Another novel PRL stimulating factor is 
salsolinol, a dopamine derived compound, synthesized in hypotha-
lamic dopaminergic neurons. Salsolinol was demonstrated to play a 
pivotal role in the mechanism of regulation of the PRL secretion in 
a lactation period. Our previous studies showed that salsolinol also 
stimulates OT expression and secretion in lactating sheep. 
The aim of the present study was to compare OTR expression in 
AP between anestrous and lactating ewes and investigate the effect 
of salsolinol on this expression.
Material and methods: The experiment was conducted on an-
estrous ewes and lactating ewes during a period of weaning (9th 
week of lactation). Two days before the experiment lambs were 
separated from their mothers to avoid the stimulation of the teats. 
5-hour infusions of salsolinol (5 × 30 µg/60 µl/30 min) or Ringer-
Locke’s (control) solutions into the III ventricle of the brain were 
performed. After the infusions the animals were sacrificed and 
AP was dissected. Total RNA from each tissue was extracted and 
converted to cDNA. The relative amount of specific OTR transcript 
was determined by the real-time qPCR. 
Results: In the lactating ewes OTR gene expression was significantly 
(p < 0.01) upregulated when compared to the anestrous ewes. 
Administered salsolinol evoked a significant (p < 0.05) increase of 
OTR gene expression in the anestrous ewes. In turn, in the lactat-
ing sheep the effect of infused salsolinol on OTR gene expression 
was not observed.
Conclusions: The upregulation of OTR gene expression in AP of 
lactating ewes may have an effect on the increased sensitivity of 
lactotrophs to the OT action and, in consequence, the increase of 
PRL release. Salsolinol may also contribute to this action.
Work was supported by NCN — grant NN 311 5171 40.
The effect of 1-MeDIQ (salsolinol’s analogue) on the 
release of corticotrophin and cortisol in lactating sheep
Małgorzata Hasiec, Elżbieta Marciniak,  
Magdalena Cieślak, Konrad Górski,  
Katarzyna Romanowicz, Tomasz Misztal 
Department of Endocrinology, The Kielanowski Institute of Animals Physiology 
and Nutrition PAS, Jabłonna
Introduction: Our recent studies show that salsolinol (1-meth-
yl-6,7-dihydroxy-1,2,3,4-tetrahydroiso-quinoline), present in 
the hypothalamus of lactating sheep, inhibits stress-induced 
hypothalamic-pituitary-adrenal (HPA) axis activity. To study 
the physiological functions of salsolinol its structural analogue 
1-MeDIQ (1-methyl-3,4-dihydroisoquinoline) has been used which 
has antagonistic properties to salsolinol especially with regard to 
the prolactin release. 
The purpose of the research was to investigate the effect of intra-
cerebroventricularly infused 1-MeDIQ on the basal activity of the 
HPA axis in lactating sheep.
Material and methods: The experiment was performed on lactat-
ing sheeps (n = 8) implanted with two guide cannulae: one into 
the third ventricle of the brain (IIIv) and the other one into the 
hypothalamus (infundibular nucleus/median eminence, IN/ME). 
Every animal was used twice at three day interval. During the 
4-hour experiments the animals were infused with Ringer-Locke’s 
(control) or 1-MeDIQ (1 µg/µL) solutions, with flow rate of 2 µL/
min. The treatment was performed in a series of four 30-min infu-
sions at 30-min intervals. Simultaneously, push-pull perfusions 
of the IN/ME were performed to measure corticoliberin (CRH) 
concentrations. Moreover, using a catheter inserted into the jugular 
vein, blood samples were collected every 10 minutes to determine 
corticotrophin (ACTH) and cortisol concentrations.
Results: The hourly distribution of hormone concentrations shows 
that 1-MeDIQ-infused group had significantly higher plasma ACTH 
concentrations during the 2nd, 3rd and 4th hours, as well as plasma 
cortisol concentration during the 4th hour of the experiments. No 
significant differences were observed in perfusate CRH concentra-
tions between 1-MeDIQ and control groups.
Conclusion: On the basis of the results obtained after the central 
1-MeDIQ treatment in lactating sheep, we suggest that salsolinol in-
hibits the basal activity of the HPA axis at least at the pituitary level.
Effect of IL-1β on melatonin secretion from sheep 
pineal explants — ex vivo study
Andrzej Przemysław Herman, Karolina Król,  
Agata Krawczyńska, Elżbieta Marciniak,  
Hanna Antushevich, Marlena Zielińska-Górska,  
Dorota Tomaszewska-Zaremba
The Kielanowski Institute of Animal Physiology and Nutrition PAS, Jablonna
Introduction: The pineal hormone melatonin plays an important 
role in the neuroendocrine control of reproductive physiology. The 
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importance of melatonin secretion for reproduction in seasonally 
breeding animals has been well established. It could be speculat-
ed that inflammation may also disturb the reproduction process 
indirectly affecting the melatonin secretion from the pineal tissue. 
The study was designed to determine the effect of interleukin 
(IL)-1β on the melatonin secretion and the expression of enzymes: 
arylalkylamine N acetyltransferase AA-NAT and O-methyltrans-
ferase (HIOMT) involved in melatonin synthesis from the pineal 
explants and to explain whether the inflammation induced by 
lipopolysaccharide (LPS) treatment affects the response to IL-1β
Material and Methods: The experiment was carried out during 
a short-day period. Animals were intravenously injected by LPS 
(400 ng/mL) or NaCl, 2 hours after sunset. The sheep were euth-
anized 3 h after the injection. Four fragments of the pineal gland 
dissected from each ewe were divided into four groups incubated 
with: (1) ‘pure’ medium 199, (2) 10 pM of Noradrenaline (NE), (3) 
75 pg/mL of IL-1β and (4) NE and IL-1β at 37°C and 95% and 5% 
CO2. The melatonin concentration in the media was assayed using 
RIA, the gene and protein expression of AA-NAT and HIOMT was 
determined using Real-Time PCR and Western Blot.
Results: IL-1β completely reduced (p < 0.01) NE stimulated the 
secretion of melatonin and the expression of AA-NAT from all 
the explants. Moreover, NE induced release of melatonin was 
significantly (p < 0.01) lower in the endotoxin treated group. No 
effect of NE or IL-1β on HIOMT gene and protein expression 
was found.
Conclusion: The obtained results suggest that IL-1β is a potent 
modulator of melatonin secretion. Some differences in the secretion 
of melatonin suggest that inflammation influences the pineal gland 
activity in a prolonged manner and it could affect its responsiveness 
even after the deprivation of inflammatory signals.
This work was supported by grant NCN UMO-2011/03/D/NZ9/04021
The influence of melatonin receptors antagonists, 
luzindole and 4-P-PDOT, on melatonin-dependent 
vasopressin release from the rat hypothalamo- 
-neurohypophysial system: in vitro studies
Marlena Juszczak, Magdalena Roszczyk
Department of Pathophysiology and Experimental Neuroendocrinology, Medical 
University of Lodz, Poland
Introduction: The aim of the present investigation was to study 
the effect of melatonin (MT) membrane receptors antagonists, i.e. 
luzindole (a non-selective antagonist of MT1 and MT2 receptors) and 
4-phenyl-2-propionamidotetralin (4-P-PDOT - a selective antagonist 
of MT2 receptor), on MT-dependent vasopressin (AVP) secretion 
from the rat hypothalamo-neurohypophysial (H-N) system in vitro.
Material and methods: Male rats served as donors of the H-N 
explants, which were placed in 1 mL of Krebs-Ringer fluid (KRF) 
heated to 37oC. Each explant was incubated successively in: 1 — 
normal KRF {fluid B1}, 2 — the incubation fluid as B1 alone or 
containing the following substances: MT (at the concentrations 
of 10–9, 10–7 or 10–3 M) and luzindole or 4-P-PDOT, or their vehicles 
{fluid B2}. After 20 min incubation, each medium was collected and 
immediately frozen before AVP estimation by the RIA.
Results: MT, at the concentrations of 10-9 and 10-7 M, significantly 
inhibited AVP secretion from the isolated rat H-N explants. Luzin-
dole significantly suppressed MT-dependent effect, while 4-P-PDOT 
did not eliminate the inhibitory influence of MT on AVP secretion 
in vitro. At the concentration of 103 M, MT significantly stimulated 
AVP release when H-N explants were incubated in the medium 
containing luzindole or 4-P-PDOT.
Conclusions: The present study demonstrates that MT1 receptor 
may contribute to the inhibitory effect of MT (at a concentration 
close to its physiological level in the blood) on AVP secretion in the 
rat. However, for the stimulatory effect of pharmacological dose of 
the hormone on AVP release, mechanisms different from MT1/MT2 
receptors are involved.
This study was supported by Medical University of Lodz (grant No 
502-03/6-103-01/502-64-013).
The estrogen-dependent modulation of prolactin 
secretion by orexins in the pituitary primary culture 
mature female rats
Malgorzata Kalisz1, Lidia Martynska1, Ewa Wolinska-Witort1, 
Magdalena Chmielowska1, Anna Litwiniuk1, Wojciech Bik1, 
Boguslawa Baranowska2 
1Department of Clinical Neuroendocrinology, Centre of Postgraduate Medical 
Education, Warsaw
2Department of Neurology, Second Faculty of Medicine Medical University of 
Warsaw 
Introduction: Orexin A (OxA) and orexin B (OxB) are 33 and 28 
amino acid hypothalamic neuropeptides involved in the regulation 
of the neuroendocrine and the reproductive system. Prolactin (PRL) 
release from the pituitary is regulated both by local factors and by 
factors originating from the hypothalamus via the pituitary portal 
circulation. Estrogen is known to have a stimulatory role in PRL 
synthesis and release.
To investigate the effect of OxA and OxB on PRL secretion in the 
pituitary primary culture mature female rat. 
Material  and method: Pituitary cells were isolated from three-
month-old mature ovariectomized female rats (OVX) and female 
OVX subcutaneous estradiol supplementation (OVX + E2). OxA 
and OxB were tested at escalating doses evaluating PRL secretion 
after 1 and 4 hours. PRL concentration was measured in the culture 
medium by radioimmunoassay (RIA).
Results: It was found that after 1 hour incubation with OxA and 
OxB the secretion of PRL increased in OVX group, however, 
decreased in OVX + E2 group compared with the control group. 
After 4 h incubation with OxB (1 nM; p < 0.05) PRL secretion was 
decreased in OVX group. In the OVX+E2 group incubation with 
OxA (100 nM p < 0.05) and OxB (1 nM; p < 0.05) decreased PRL 
secretion compared with the control group.
Conclusion: It was demonstrated that OxA and OxB may modulate 
prolactin secretion depending on estrogen status of female rats and 
the duration of pituitary incubation.
This study was supported by CMKP grants 501-1-31-22-13 and 
501-1-31-22-13.
Giant prolactinomas (GP) therapeutic and diagnostic 
challenges
Aldona Kowalska1 Iwona Pałyga1 Danuta Gąsior-Perczak1 
Wiesław Bonicki2
Department of Endocrinology Holycross Cancer Centre, Kielce, Poland, Depart-
ment of Neurosurgery, The Maria Skłodowska-Curie Memorial Cancer Centre and 
the Institute of Oncology, Warsaw, Poland
Introduction: GP are rare pituitary tumors. The prevalence ranges 
between 0.5–4.4% of all pituitary tumors and exceeds about 4% of 
prolactinomas. Due to the different directions of expansion GP can 
manifest in a diverse set of symptoms. Very large sizes of GP and infil-
tration of relevant structures of the brain cause a therapeutic challenge.
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The aim of this work is to present our own experience with patients 
with GP. The characteristic of the patients: there has been 7 patients 
treated with GP in our centre: 2 women and 5 men. Women aged 
42 and 45: hormonal disturbances (primary or secondary amen-
orrhoea) 2/2, without an impairment of other tropic functions 0/2. 
Mass effect symptoms: persistent headaches 2/2 with no visual 
disturbances 0/2. Prolactin (PRL) level at diagnosis — 62000-100933 
mIU/L (N: < 540 mIU/mL). Maximal dimension of the tumors were 
70 and 61 mm. Treatment with dopamine agonists (AD) in the first 
patient caused reduction in tumor size and normalization of PRL 
level. In the second patient: combined treatment with neurosurgery 
(NS) + AD -macroscopic removal of the tumor and AD caused 
normalization of prolactin levels and restoration of the menses but 
after AD treatment. Men in the age of 23 to 53 years. Hormonal dis-
turbances: pituitary multiaxial 2/5, mass effect symptoms: headaches 
5/5, visual acuity 5/5, temporal visual field defect 2/5, diplopia 1/5. 
PRL levels from 189900 mIU/L to 230269 mIU/L (N: < 360 mIU/mL). 
Maximal tumor size from 45mm to 55 mm. Treatment only with AD: 
4/5, associated Nch AD-1/5. Reducing tumor size: 5/5 normalization 
Prl 3/5. Diagnostic trouble: 2/7 initial laryngological diagnosis as 
sphenoid and ethmoid sinus tumors with the destruction of bone.
Conclusions: 
1. Due to the different clinical picture GP may cause a diagnostic problem
2. There is need for combined therapy in many cases of GP. 
Influence of thyreoliberin (TRH) on the regulation of 
the myofibroblasts isolated from cardiac infarction scar
Anna Krzymińska, Jacek Drobnik, Alicja Szczepanowska, 
Joanna Ciosek
Department of Neuropeptides Research Chair of General and Experimental Patho-
logy, Medical University of Lodz, Poland
Introduction: Thyreoliberin (TRH), synthesized in the hypothala-
mus, is also produced peripherally where it exerts its effects via TRH 
receptors which have been detected, inter alia, in the heart. It has 
shown a positive inotropic effect on the cardiovascular system in 
myocardial infarction scar which is probably due to TRH protec-
tive influence on the contractility of the necrotic area. Fibroblasts 
migration and proliferation as well as their transformation into 
myofibroblasts are crucial for a post-infarction scar formation. For 
strengthening and remodeling of a scar, the deposition of extracel-
lular matrix produced by myofibroblasts particularly of collagen 
fibers, is essential and associated with the increased area rigidity 
and the progressive development of the heart failure. Controlling 
the activity of myofibroblasts will allow defining the antiremodeling 
treatment of myocardial infarction. 
The aim of the study was to clarify whether and in what way the 
action of myofibroblasts is regulated by TRH as well as by TRH 
analog (taltirelin).
Material and methods: Myofibroblasts were obtained from rats 
with the induced myocardial infarction. The influence of TRH was 
investigated in cultures with the addition of TRH and taltirelin. 
The metabolism of myofibroblasts was evaluated by measuring the 
concentration of total collagen.
Results: The TRH concentration range from 1*10–11 to 1*10–7M 
similarly to taltirelin increases the total cells number but contrary 
to TRH analog it inhibits collagen synthesis. 
Conclusions: The reported data indicate that taltirelin acting in CNS 
via TRH-R1 receptors shows (like TRH) antinociceptive and anti-
depressant influence. This effect differs from the results obtained 
from myofibroblasts culturing.
The research was funded by the Medical University of Lodz (grant 
No 503/6-103-02/503-01).
The effects of somatostatin analogues treatment  
in patients with non-functioning pituitary adenomas 
and in acromegaly as primary and secondary therapy
Jolanta Kunert-Radek1, Natalia Zawada1,  
Marek Pawlikowski2, Hanna Pisarek3, Maciej Radek4
1Clinic of Endocrinology, Medical University of Lodz
2Department of Immunoendocrinology, Medical University of Lodz 
3Department of Neuroendocrinology, Medical University of Lodz 4Clinic of Neuro-
surgery and Peripheral Nerve Surgery, Medical University of Lodz
Introduction: Somatostatin analogues (SSA) are used in the treat-
ment of somatotropinomas and thyreotropinomas. The latest pub-
lications focus on the use of these drugs in the therapy of clinically 
non-functioning pituitary adenomas (NFPA), especially in recurrent 
tumours after incomplete surgical resections.
Material and methods: The effectiveness of SSA therapy in patients 
treated in The Department of Clinical Endocrinology in Lodz was as-
sessed. The material involved 40 acromegalic patients and 22 patients 
with NFPA treated by SSA up to ten years. Hormonal profile, the dy-
namics of tumour size changes, ophthalmic exam with the assessment 
of visual field, somatostatin receptor scintigraphy, the immunohisto-
chemistry of operated tumours and of somatostatin receptor subtypes 
as well as patients’ quality of life and undesirable effects were analysed.
The effects of SSA treatment in patients with NFPA in comparison 
to patients with acromegaly.
Results: The significant decrease of growth hormone and IGF-1 
concentrations was noticed in 95% of the patients with acromegaly 
(16 recurrent tumours and 24 primary tumours). The complete nor-
malisation of hormone levels was observed in 50% of patients. The 
evaluation of tumours’ size in MRI revealed the significant reduction 
of tumour volume in 40% of patients. Most of tumour regression 
was noticed in primary adenomas. There was the improvement of 
quality of life and clinical condition in nearly all the patients. 5% 
of the patients developed symptomatic cholelithiasis that regarded 
an operation. Considering NFPA (17 — recurrent tumours and 5 
primary tumours), the stabilization of tumour size and visual field 
was observed in 68% of the patients while the reduction of tumour 
volume was noticed in 9% of the cases. In 23% of the patients there 
was the increase of adenoma size that was qualified for operation.
Conclusions: Generally, somatostatin analogues are effective in the 
treatment of acromegaly. In the patients with NFPA the effective-
ness of SSA is much lower. However, in the most cases of NFPA the 
pharmacotherapy with SSA leads to the stabilisation of the disease 
and can be considered as an alternative for the next neurosurgery.
Endoscopic endonasal transsphenoidal approaches 
for pituitary adenomas invading the cavernous sinus
Jacek Kunicki, Wiesław Bonicki
Department of Neurosurgery, M. Sklodowska-Curie Memorial Cancer Center and 
Institute of Oncology, Warsaw
Introduction: The endoscopic pituitary surgery offers technical 
possibilities to visualize and access better the tumor extensions 
invading parasellar areas. The significant number of pituitary 
adenomas present an invasive growth pattern. The cavernous 
sinus invasion is a significant predictor of an unfavorable outcome 
Aim of the study was to report the results of a consecutive series 
of patients who underwent an endoscopic endonasal approach 
(both transsellar or extended — direct) for the resection of pituitary 
adenomas invading the cavernous sinus.
Material and methods: The retrospective review of clinical and 
radiographic outcomes of a consecutive series of patients operated 
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at our center between 2008 and 2013 was performed. The cavernous 
sinus invasion was defined preoperatively according to Knosp scale 
III and IV, only cases with intraoperative endoscopic inspection 
confirmed the invasion of CS were included into the study.
There were 168 patients with the confirmed cavernous sinus 
(28% macroadenomas), there were 42 cases with Knosp IV, and 
126 cases defined as Knosp III. The tumors included non-func-
tioning adenomas in 94 cases (54%), growth hormone-secreting 
adenomas in 46, prolactin-secreting adenomas in 24, and adreno-
corticotropic hormone-secreting adenomas in 4 cases.
Results: The radical resection of cavernous sinus invasive NFPAs was 
observed in 41 (44%) cases. Normal growth hormone and insulin-like 
growth factor 1 levels were achieved in 19 patients (41%) with growth 
hormone adenomas. The endocrinological remission was achieved in 
13 patients with prolactinomas and 2 patients with adrenocorticotropic 
hormone-secreting adenomas. There were no mortalities in the series, 
the transient oculomotor nerve palsies were observed in 8 patients 
(4.7%).
Conclusions: Endoscopic endonasal approach offers a chance for 
radical cure to the patients with adenomas cavernous sinus invasion 
with a minimal risk of surgical complications.
Clinicopathological analysis of hormone 
immunonegative silent gonadotroph adenomas  
(so called null cell — gonadotroph adenomas)
Jacek Kunicki1, Maria Maksymowicz2, Wiesław Bonicki1
1Department of Neurosurgery, M. Sklodowska-Curie Memorial Cancer Center and 
Institute of Oncology, Warsaw
2Department of Pathology and Laboratory Diagnostics, M. Sklodowska-Curie 
Memorial Cancer Center and Institute of Oncology, Warsaw
Introduction: The gonadotroph adenomas (GA) are one of the most 
common non-functioning pituitary adenomas treated surgically. There 
is a subpopulation of GA with low morphological and functional differ-
entiation with lack of immunoreactivity to anterior pituitary hormones, 
in previous decades those tumors were classified as null cell adenomas.
The ultrastructural evaluation with electron microcopy or immu-
nohistochemical characterization of pituitary transcription factors 
in majority of cases of the so called null cell adenomas show the 
differentiation into GA.
The aim of the study was to define the morphology and clinical 
presentation of this subgroup of GA.
Material and methods: Out of 447 non-functioning pituitary 
tumors treated surgically within last 5 years, 38 (8.5%) hormone 
immunonegative silent gonadotroph adenomas were diagnosed 
using immunohistochemical and electron microscopic evaluation.
Results: There was significant women predominance 23/38 (60%). All of 
those tumors were diagnosed as macroadenomas, in 7 cases (18.4%) the 
tumors were classified as giant adenomas (> 4 cm).The main clinical pres-
entation were progressive visual worsening and headaches. The MRI and 
intraoperative inspection showed that 19/38 (50%) of HNGA were invasive 
adenomas. The cavernous sinus invasion was the most common direction 
of invasion — 12 cases (31.5%). Coexisting different routes of invasion were 
observed in 44% of cases. The morphometric evaluation of HN GA did not 
show significant differences between immunopositive and immunonega-
tive gonadotroph adenomas. The results of endoscopic surgical resection 
were better for HN GA than for HIP GA (80% GTR vs. 72% GTR) but the 
difference was not statistically significant (Fisher exact test p = 0.17) 
Conclusions: Results of analysis show that clinical course and 
morphological appearance did not significantly differ hormone 
immunonegative silent gonadotroph adenomas (so called null cell 
— gonadotroph adenomas) from other GA. There was significant 
female predominance for those tumors.
Endoscopic endonasal resection of giant pituitary 
adenomas
Jacek Kunicki, Paweł Poppe, Wiesław Bonicki
Department of Neurosurgery, M. Sklodowska-Curie Memorial Cancer Center and 
Institute of Oncology, Warsaw
Introduction: The advances of an endoscopic technique allow the 
resection of pituitary tumors previously operated by transcranial 
approaches. 
The aim of the study was to review the early surgical results in 
a series of patients with giant pituitary adenomas operated with 
endoscopic endonasal approach.
Material and methods: The study is a retrospective analysis of 
a series of 72 patients with giant pituitary adenomas operated at 
the Department of Neurosurgery Memorial Oncological Center in 
Warsaw from 2008 to 2014.
Results: The gross total resection was accomplished in 35 out of 
72 cases (48.6%), the subtotal resection was achieved in 30 of 72 
patients (42%), in 7 cases only the partial resection was possible. 
There were no mortalities in the series. Postoperatively 86% of the 
patients showed varying improvement in visual field defects and 
visual acuity. There was no visual function deterioration in the 
series. Two patients presented early postoperative CSF leak and 
were reoperated. During a mean 42 month observation there were 
5 cases of recurrences and 8 cases of residual tumor progression.
Conclusions: Our results indicate that resection with endoscopic 
endonasal approach can be a safe and effective method for the 
treatment of patients with giant pituitary adenomas and it is the 
alternative for transcranial approaches.
Are the “classic” and the “modern” forms of 
Nelson’s syndrome the same or different disorders?
Maria Kurowska, Joanna Malicka, Jerzy S. Tarach
Department of Endocrinology, Medical University, Lublin
Introduction: Nowadays a great heterogeneity in the diagnostic 
criteria and clinical picture of Nelson’s syndrome (NS) is observed 
and a formal consensus about its current definition does not exist. 
Aim was to answer the title question by the presentation of 8the 
clinical and therapeutic differences of both forms of NS based on 
2 case reports. 
Material and methods: Retrospective analysis of clinical picture 
and diagnostic and therapeutic procedures. 
Case 1. A 54 year-old woman. Cushing’s disease caused by mi-
croadenoma was diagnosed and bilateral adrenalectomy was 
performed 30 years ago. 5 years later she developed NS [pituitary 
macroadenoma and skin hyperpigmentation]. In the consecutive 
imaging studies the increasing of the tumor size was observed. 
Adenoma apoplexy evoked a considerable but transient tumor 
shrinkage 8 years ago. The re-growth of the tumor was an indication 
to neurosurgery 5 years ago. Since this moment a slow progression 
of tumor size has been observed and the patient needs only a hy-
drocortisone substitution. 
Case 2. A 56-year-old woman with pituitary microadenoma and 
Cushing’s disease diagnosed 7 years ago. She underwent trans-
sphenoidal adenomectomy followed by a 27-month-long remission. 
Due to a tumor re-growth consecutive 2 transsphenoidal reoper-
ations and stereotactic radiotherapy were conducted. Afterwards, 
because of sustained hypercortisolism, bilateral adrenalectomy 
was performed. Then the patient developed Nelson`s syndrome. 
Propter a rapid tumor’s recurrence a 4th transsphenoidal surgery 
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and right fronto-temporal craniotomy were performed. Only 9 
cycles of temozolomide resulted in marked clinical and radiological 
improvement. After a pause in chemotherapy a consecutive relapse 
occurred. Then bevacizumab, resulting in the clinical stabilization 
of disease, was introduced. Propter next tumor re-growth she un-
derwent left fronto-temporal craniotomy. 
Conclusion: It appears evident that the “classic” and “modern” 
form of Nelson’s syndrome are different diseases. 
Astrocytes GFAP mRNA expression under different 
glycemic conditions
Anna Latacz, Ewa Ocłoń, Joanna Zubel-Łojek,  
Krystyna Pierzchała-Koziec 
Department of Animal Physiology and Endocrinology, Faculty of Animal Sciences, 
University of Agriculture Krakow, Poland
Introduction: Astrocytes are the main homeostatic cells of the 
central nervous system and play a wide role in the physiology and 
pathology of the CNS. Astrocytes activity is controlled by several 
kinases e.g. mammalian target of rapamycin — mTOR and can be 
modified in pathological conditions like metabolic changes. Reactive 
astrocytes are capable of producing a variety of active molecules 
e.g. pro-inflammatory mediators.
The aim of this study was to evaluate the effect of various glucose 
concentrations on astrocyte functions, estimated by mRNA expres-
sion of glial fibrillary acidic protein - GFAP, cells proliferation rate 
and the level of visfatin secretion.
Material and methods: Rat primary cortical astrocytes were incubated 
for 24 hours in medium with different concentrations of glucose 
(lower: 5 mM, higher: 67.5 mM) and mTOR inhibitor — rapamycin 
(10 nM). Culture medium was collected and visfatin concentration was 
measured by commercial enzyme-linked immunosorbent assay. The 
activity of astrocytes was evaluated by quantitative PCR measurements 
of GFAP mRNA expressions and cells proliferation rate.
Results: Significant differences between control and experimental 
groups have been detected. Lower and higher glucose conditions 
increased visfatin release by 235% and 49% respectively. Rapamycin 
addition caused the increase of GFAP mRNA expression and, at the 
same time, reduced the proliferation rate of the cells incubated in 
medium with abnormal glucose concentration.
Conclusions: 
1. Astrocytes are the central source of visfatin release in pathologi-
cal conditions. 
2. The changes of astrocytes activities showed a modulating effect 
of mTOR inhibitor depending also on the glucose conditions. 
3. Astrocytes are the cells that are able to react in response to pe-
ripheral glucose abnormalities and their biochemical features are 
related to mTOR pathway.
Supported by: DS3243/KFiEZ
The effect of sodium valproate (VPA) on LH secretion 
from rat pituitary cells after the stimulation  
with endothelin-1 (ET-1) in primary culture
Anna Litwiniuk1, Malgorzata Kalisz1, Justyna Skrzypska1, 
Ewa Wolinska-Witort1, Lidia Martynska1,  
Magdalena Chmielowska1, Alina Gajewska2,  
Elzbieta Wasilewska-Dziubinska1, Wojciech Bik1
1Department of Clinical Neuroendocrinology, Centre of Postgraduate Medical 
Education, Warsaw, Poland
2Department of Neuroendocrinology, The Kielanowski Institute of Animal  
Physiology and Nutrition Polish Academy of Sciences, Jabłonna, Poland
Introduction: The presence of ET-1, a peptide having a vasoconstrictor 
activity, in the hypothalamus and pituitary, suggested the possibility 
of the regulatory action of ET-1 in neuroendocrine cells. It has been 
shown, that ET-1 and GnRH induced the comparable secretion of 
LH. However, the dynamics of action of ET-1 is different from the 
dynamic action of GnRH. Previously we have shown that VPA inhibits 
GnRH-stimulated LH release from pituitary cells. At present it is not 
known whether VPA affects also the secretion of LH stimulated by ET-1.
The aim of the study was to evaluate the effect of VPA on the secre-
tion of LH from the pituitary cells stimulated by ET-1.
Material and methods: The pituitary were taken to the in vitro study 
from sexually mature male Wistar rats. The primary pituitary cells 
culture (5x105 cells/well) was incubated 0,5, 1 and 3 h with alone ET-1 
(100 nM) or combined with different doses of (100 nM, 1 µM and 10 
µM). LH concentrations in medium were assayed by RIA method.
Results: It was observed that after 0.5 h (p < 0.05) and 1 h (p < 0.001) 
incubation with ET-1 (100 nM) the secretion of LH was increased. In 
turn, after 1 h incubation VPA (1 µM; 10 µM, p < 0.001) abolished 
the stimulated by ET-1 secretion of LH from the pituitary cells. 
Conclusions: VPA in a dose and time-dependent manner inhibits 
the stimulated by ET-1 secretion of LH from the pituitary cells.
This study was supported by CMKP grants No 501-1-31-22-13 and 
501-1-31-22-14.
A case report of a patient with congenital 
hypopituitarism, in whom a dysfunction of particular 
axis appeared in different times
Katarzyna Lizis-Kolus1, Aldona Kowalska1, Ewa Piątkowska2
1Department of Endocrinology, Holy Cross Cancer Centre, Kielce, Poland 
2Department of Endocrinology and Diabetology, Regional Children’s Hospital, 
Kielce, Poland
Introduction: Congenital combined pituitary multihormone defi-
ciency is usually diagnosed in childhood. In the natural history of 
the disease the occurrence of subsequent tropic hormone deficiency 
is possible at different times.
Aim of the study: Description of a patient aged 43 with congenital 
hypopituitarism and a gradual falling tropic function. 
Material and methods: At the age of nine growth hormone defi-
ciency was diagnosed. For two years the patient was treated with 
rhGH. Achieved height of 167 cm. 
MRI of the pituitary: Empty sella syndrome-the greater part of the 
anterior lobe flattened, pressed against the bottom of the saddle; 
a part of the nervous ectopic located in the hypothalamus. At 
28 years of age the patient was diagnosed with the deficiency of 
pituitary axes in the range of gonadotropic and corticotropic with 
hyperprolactinaemia. Enabled substitution steroid testosterone 
formulation, a dopamine agonist. Because of the elevated TSH to 
normal fT4, fT3 and a/TPO, TRH test was performed. Diagnosed 
with primary hypothyroidism. Thyroid ultrasound: PP — 9 × 11 
× 24 mm, LP — 8 × 7 × 28 mm; hypoechoic thyroid gland without 
focal lesions. Enabled substitution of L-thyroxine. After one year, the 
decline in the concentrations of TSH and fT4, fT3 was observed. TRH 
test was repeated. Diagnosed with an underactive pituitary thyro-
tropic axis and modified L-thyroxine therapy for normalization of 
fT4, fT3. The patient remains in the observation of the substitution 
treatment continuation because of multihormonal hypopituitarism 
accompanied by hyperprolactinaemia. 
Conclusions: 
1. Patients with congenital hypopituitarism require chronic endo-
crine observations. 
2. In the case of hypopituitarism in the range of one axis, developing 
deficiency of other axes is possible later. 
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3. The occurrence of primary hypothyroidism in patients with 
hypopituitarism, does not preclude the development of second-
ary hypothyroidism in the course of the deficiency of pituitary 
thyrotropic axis.
The role of pathomorphological diagnosis  
of pituitary tumors in patients with clinical 
symptoms of hyperprolactinemia
Maria Maksymowicz1, Grzegorz Zieliński2,  
Przemysław Witek3, Ewa Matyja4, 5, Renata Jonasz1, 
Monika Pękul1, Jacek Kunicki5, Wiesław Bonicki5
1Department of Pathology, M. Sklodowska-Curie Memorial Cancer Center and 
Institute of Oncology, Warsaw
2Department of Neurosurgery, Military Institute of Medicine, Warsaw
3Department of Endocrinology and Isotope Therapy, Military Institute of Medici-
ne, Warsaw
4Department of Experimental and Clinical Neuropathology, M. Mossakowski 
Medical Research Centre, Polish Academy of Sciences, Warsaw
5Department of Neurosurgery, M. Sklodowska-Curie Memorial Cancer Center and 
Institute of Oncology, Warsaw
Introduction: Prolactinomas are the most frequent tumors of adeno-
hypophysis, but surgical treatment is usually reserved for patients 
with resistance or intolerance for medical therapy. It is important 
to differentiate hyperprolactinemia due to the “stalk effect” (the 
compression of the infundibulum) from the one caused by the pi-
tuitary tumor secretion. An accurate diagnosis with the application 
of immunohistochemistry (IHC) and electron microscopy (EM) 
makes possible a proper prognosis and appropriate postoperative 
management (e.g. discontinuation of medical treatment). 
The aim of the study was the evaluation of the practical imple-
mentation of IHC and EM techniques in the diagnosis of surgically 
treated prolactinoma.
Material and methods: At the Department of Pathology of Cancer 
Center 3660 cases of consecutive surgically resected pituitary tumors 
were evaluated between 1998 and 2014. Among them there were 
158 patients with hyperprolactinemia. All the cases were diagnosed 
by IHC and EM. The MIB-1 proliferative index was determined. 
Results: In our material only 67.1% patients with clinically diagnosed 
hyperprolactinemia (prolactin values of more than 200 ng/mL) have 
PRL-cell adenoma. In contrast, 26 gonadotroph, 9 mixed GH/PRL, 
9 silent adenomas, 5 somatoptroph and 1 acidophil stem cell adenoma 
were diagnosed. Among nonadenomatous tumors 1 xanthogranuloma 
and 1 case of lymphocytic hypophysitis were revealed.
Conclusions: Our results confirmed the practical value of complex 
histopathological diagnosis in recognizing the cases of pseudoprol-
actinoma. In the cases of overlapping immunohistochemical profiles 
an ultrastructural analysis is valuable to provide useful information. 
Proliferative markers, like MIB-1, may be helpful in the diagnosis 
of invasive, low differentiated tumors.
Newly identified neuropeptides involved  
in regulation of body weight and energy 
homeostasis
Ludwik K. Malendowicz, Marcin Ruciński,  
Agnieszka Ziołkowska
Department of Histology and Embryology, Poznan University of Medical Sciences
Neuropeptides regulate energy homeostasis primarily in re-
sponse to signals from both the adipose tissue and the gastro-
intestinal tract. Under normal conditions the interrelationship 
between the adipose tissue and neuropeptides maintains proper 
body weight. In recent years only a few novel neuropeptides 
have been identified and it has been suggested that some of 
them are involved in the regulation of body weight and energy 
homeostasis. Regarding this, available data on three neuropep-
tides will be presented. Spexin (SPX) is a neuropeptide closely 
related to galanin (GAL) and interacts with GALR2/3 receptors. 
Because of its widespread expression, SPX is probably involved 
in many different physiological functions. It is interesting that 
the expression of SPX gene is markedly down-regulated in the 
obese human adipose tissue. In rodents SPX protein induces 
weight loss in DIO (diet-induced obesity) rodents. Neuropep-
tide QRFP (26RFa) is a 26-amino acid residue peptide that was 
originally identified from the frog brain. It is highly expressed in 
the hypothalamus of vertebrates. QRFP has been shown to exert 
orexigenic activity in mammals, acting throughout GPR103 (QRF-
PR). Augurin is a product of a esophageal cancer-related gene-4 
(ECRG4). ECRG4 mRNA is widely expressed in normal human 
tissues. The intra-paraventricular nucleus (iPVN) administration 
of augurin (71–148) stimulates food intake in male Wistar rats.
This study was supported by a grant IP2011 046671 from the Min-
istry of Science and Education in Poland.
Acromegaly as the first manifestation of MEN 1 
syndrome — case report
Joanna Malicka, Maria Kurowska, Patrycja Nowicka-Stążka, 
Jerzy S. Tarach
Department of Endocrinology, Medical University, Lublin, Poland
Introduction: Pituitary adenomas occur with an incidence of 
77.6/100 000, with adenomas derived from somatotrophs and 
secreting GH accounting for 50–70 cases/1 million. About 5% of 
GH-secreting adenomas occur with a familial aggregation, as 
a part of MEN-1, MEN-4, Carney complex or family bound isolated 
pituitary adenomas-FIPA. Until now, both the clinical picture and 
the genetic background of MEN-1 have been well recognized. 
MEN-1 syndrome is inherited in an autosomal dominant pattern. 
Its most frequent clinical components are: hyperparathyroidism 
(95%), endocrine enteropancreatic tumors (60%) and pituitary 
adenomas (42%). Among pituitary adenomas, 9% secrete growth 
hormone and cause acromegaly with mean recognition between 
30 and 50 years of age. 
The aim of this study was to present the patient in whom acromeg-
aly was the first manifestation of MEN-1 syndrome. 
Case report. A 65-year-old woman with acromegaly recognized 
in September 2009 (GH > 40 ng/mL, n < 5 ng/mL; IGF1–1127 ng/mL, 
n: 75–212). MRI revealed 13 × 16mm pituitary macroadenoma. 
In August 2010 CT confirmed 18 × 12 mm adenoma of the left 
adrenal gland and 36 × 26 × 54 mm retroperitoneal tumor 
localized in the pancreatic area with elevated Ca19–9 marker. 
Three months later, because of laboratory features of primary 
hyperparathyroidism (Ca = 10.5–11.0 mg/dL, n: 8.7–10.4 mg/dL; 
PTH = 110–124 pg/mL, n: 14–72) MIBI scintigraphy was per-
formed and confirmed the enlargement of the right inferior 
parathyroid gland. Nodular goiter, uterine myoma and skin 
fibroma were also present. The patient didn`t accept the pro-
posal of surgery and now she receives somatostatin analog and 
remains in follow-up. 
Conclusion: Our patient presents the clinical features typical of 
MEN-1, with the rare type of pituitary adenoma as a part of it. 
What is more, acromegaly was the first symptom of the syndrome. 
However, in order to confirm the diagnosis, conducting genetic 
tests should be considered. 
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The incidence of neoplasms in acromegaly  
— own observation 
Joanna Malicka, Maria Kurowska, Jerzy S. Tarach
Department of Endocrinology, Medical University, Lublin, Poland
Introduction: Pituitary adenomas derived from somatotrophs 
occur with an incidence of 50-70/million. The excessive secretion 
of GH leads to the increased production of growth factors, (mainly 
insulin-like growth factor-1) in the liver and other tissues. IGF-1 
stimulates cell division that, in turn, increases the risk of benign and 
malignant tumors and leads to the higher mortality rate of patients. 
The aim of the study was to estimate the prevalence of various 
tumors in acromegaly patients in own material. 
Material and methods: The material covered 57 acromegalics (35 F 
and 22 M) treated from 2000 in Department of Endocrinology and 
Endocrinological Outpatient Clinic. We studied the medical histories 
and the results of patients` diagnostic investigations. 
Results: There were 85 benign and 4 malignant tumors in our group. 
Nodular goiter was the most common (39 cases) with 13 cases of 
hyperthyroidism and 26 with euthyroidism. Gastrointestinal tract 
endoscopic examination was performed in 23 patients (40.4%) 
with 20 colonoscopies and 9 gastroduodenoscopies. 16 colorectal 
polyps, 1 gastric polyp, 1 polyp of gallbladder, 1 colorectal cancer 
and 1 gastric cancer were found. Uterine myoma were detected in 
6 women, endometrial carcinoma in 1 and uterine cervix polyps in 
3. Breast carcinoma was found in 1 patient and breast fibroma in 
2 cases. 8 men were treated because of prostatic adenoma. Benign 
skin neoplasms were diagnosed in 7 cases. There was 1 case of 
pancreatic and adrenal tumor and 1 case of parathyroid adenoma. 
In 23 patients we diagnosed one tumor, in 18-two, in 5-three, in 
2-four and in 1 woman-seven various tumors. Only in 8 patients 
from the whole group we did not find such pathologies. 
Conclusion: The great number of tumors in acromegaly patients 
requires precise diagnostics. Gastrointestinal endoscopic proce-
dures, thyroid testing, gynecological and urologic examination 
should be obligatory.
The influence of Orexin B on LH secretion  
from mature rat pituitary cells in primary culture
Lidia Martyńska1, Ewa Wolińska-Witort1,  
Magdalena Chmielowska1, Małgorzata Kalisz1, Anna 
Litwiniuk1, Wojciech Bik1, Bogusława Baranowska2
1Department of Clinical Neuroendocrinology, Centre of Postgraduate Medical 
Education, Warsaw
2Department of Neurology, Second Faculty of Medicine Medical University of 
Warsaw, Warsaw
Introduction: Orexins A and B (OxA and OxB) are peptides synthe-
sized mainly in the lateral hypothalamus. They show a wide effect 
in central nervous systems as well as in peripheral tissues. Orexins 
are involved not only in the regulation of food intake, locomotor 
activity and energy expenditure but also can influence pituitary 
hormones secretion. Orexin B acts through orexin receptor type 
two (OX2R) which is found in the pituitary. 
The aim of the study was to examine the direct impact of OxB on 
LH secretion from pituitary cells of sexually mature rats.
Material and methods: Pituitaries for in vitro study were taken from 
3-months old mature female rats, one week after surgical removal 
of the ovaries (OVX), as well as from females OVX treated with 
estradiol given subcutaneously (OVX + E2). The primary pituitary 
cells culture (5 × 105 cells/well) was incubated with different doses 
of OxB (0,1 nM, 1 nM, 10 nM and 100 nM) for 1 h and 4 hs. The 
cultured cells without OxB constituted the control group. LH con-
centrations in medium were assayed by RIA method.
Results: We found that after 1 h incubation OxB did not change 
LH secretion in OVX + E2 group, and increased the secretion of LH 
by 18% (0.1 nM OxB; p < 0.05) in OVX group when compared to 
the control group. After 4 h OxB decreased LH secretion by 31% 
in both OVX + E2 (10 nM, p < 0.05) and OVX group (100 nM, p < 
0.05) as compared to the control group.
Conclusions: The obtained results indicate that OxB could slightly 
modify LH secretion and its effect depends on the dose and du-
ration of action.
The study was supported by CMKP grants No 501-1-31-22-13 and 
501-1-31-22-14.
Course of prolactinoma in pregnancy in patients 
treated in the Department of Endocrinology,  
Holy Cross Cancer Center in Kielce
Estera Mikina, Katarzyna Lizis-Kolus, Aldona Kowalska
Department of Endocrinology, Holy Cross Cancer Center in Kielce
Introduction: Prolactinoma can often be the cause of infertility. The 
use of dopamine agonists inhibits the excessive production of pro-
lactin and allows many patients to become pregnant. Proceedings 
of prolactinomas in pregnancy, despite many years of experience, 
can be a problem.
Aim of the study: The authors present a different course of the 
disease during pregnancy in women with prolactinoma. We 
observed 6 pregnant women with prolactinoma. 3 patients had 
pituitary macroadenoma prior to pregnancy, in the remaining 
3 — microadenoma was diagnosed. 5 patients were receiving 
treatment with bromocriptine before pregnancy; 1 was treated 
with chinagolid. In all the women drugs were discontinued when 
pregnancy was detected. 1 patient had the progression of tumor 
size and cranial nerve III paralysis. After restarting treatment with 
bromocriptine, the complete resolution of symptoms was achieved 
and the treatment was maintained until the end of pregnancy. In 2 
patients with macroprolactinoma a pituitary hemorrhage apoplexy 
occurred leading to the cure of the prolactinoma in one of them. 
No patients required surgical treatment of prolactinoma during 
pregnancy. In all the described patients the pregnancy ended at 
the time of birth of a healthy baby. In 2 patients a caesarean section 
terminated the pregnancy due to obstetric indications, the other 
four had natural vaginal birth.
Conclusions: 
1. Women with prolactinomas in pregnancy require careful endo-
crinological observation.
2. Progression of tumor size and tumor stroke are the most common 
complications of prolactinomas in pregnancy. 
3. In the case of the size of the tumor progression, the return to the 
treatment with dopamine agonists give rapid clinical improvement.
The role of salsolinol in regulating physiological 
processes in mammals 
Tomasz Misztal
The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of 
Sciences, Jabłonna, Poland 
Salsolinol (1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline) 
is synthesized in the central nervous system by dopaminergic 
neurons. Early reports equated the presence of this compound 
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with various types of functional disorders of the dopaminergic 
system, characteristic, in particular, of Parkinson’s disease or alcohol 
addiction. Opinions as to the harmful effects of salsolinol changed 
when its role in lactating females was discovered. Studies on rats 
and ewes showed its involvement in stimulating prolactin secre-
tion. Salsolinol is currently believed to be one of the hypothalamic 
factors stimulating both the synthesis and the release of prolactin. 
The stimulus that releases salsolinol during lactation is sucking. The 
presence of salsolinol in the hypothalamus and median eminence 
of ewes during lactation also suggests a role for this compound in 
mechanisms regulating other processes in which dopamine has 
been found to play a part, i.e., in processes determining adaptation 
of a female to lactation and rearing of an offspring. Especially note-
worthy is the inhibition of reproductive activities and the reduction 
of lactating females’ sensitivity to stress. The studies conducted at 
the Kielanowski Institute of Animal Physiology and Nutrition on 
ewes in vivo and in vitro, using exogenous salsolinol or its analogue 
with antagonistic properties, show that during lactation, salsolinol 
is a modulator of secretory activity not only of pituitary lactotrophs, 
but of entire hypothalamic-pituitary axes, including gonadotropic 
(GnRH-LH) and corticotropic (CRH-ACTH) axes. It has also been 
suggested that salsolinol participates in the regulation of oxytocin 
secretion. The development of methods for experiments on the 
central nervous system of sheep may predispose this species for use 
as an experimental model for the studies on the activity of neuronal 
systems in various physiological states or induced pathological ones. 
Changes in plasma corticosterone and IL-1β during 
the stimulation of the bed nucleus of the stria 
terminalis and the central nucleus of the amygdala in rats
Dorota Myślińska1, Ziemowit Ciepielewski1, Mateusz 
Karnia2, Agnieszka Wądołowska1, Katarzyna Czerwiec1, 
Jan Ruciński1, Karolina Plucińska1, Magdalena Podlacha1, 
Kacper Ptaszek1
1Department of Animal and Human Physiology, University of Gdansk
2Department of Biochemistry, Academy of Physical Education and Sport, Gdansk 
Introduction: The central nucleus of the amygdala (CeA) is a limbic 
structure involved in the fear conditioning and modulation of cogni-
tive functions. The bed nucleus of the stria terminalis (BST) is a part 
of “the extended amygdala”, a formation responsible for emotional 
aspects of behavior. On the basis of our previous study we assumed 
that BST and CeA also influenced the primary antitumor immune 
response. In the present study we investigated the influence of 
14-day electrical stimulation of the CeA and BST on corticosterone 
(COR) and IL-1β level and behavioral response.
Material and methods: Male Wistar rats implanted with electrodes 
into CeA or BST were divided into groups: CeA or BST stimulated, 
CeA or BST sham. Current intensity (70–160 µA; 50 Hz) was raised 
incrementally in 30-s trials until a behavioral reaction in Opto Vari-
mex Minor actometer was observed. Blood samples were collected 
by heart puncture. COR level was determined by radioimmunoas-
say, IL-1β was quantified using ELISA.
Results and conclusion: The stimulation of the CeA caused the 
decrease in IL-β concentration, the augmentation of COR (p < 
0.001) correlated with an increase in the average number of move-
ments in vertical plane imitating escape behavior. Contrary to CeA, 
BST stimulation results in the increase in IL-β level and locomotor 
activity, without any effect on COR. We suggest that the hormonal 
outcome of the CeA and BST stimulation plays a crucial role in the 
regulation of behavioral and immune effects.
Supported by: NN303819040.
The role of orexins in the regulation of energetic 
metabolism
K.W. Nowak1, M. Skrzypski1,2, E. Pruszyńska-Oszmałek1,  
P Kaczmarek1, P. Kołodziejski1,2, T. Wojciechowicz1,  
D. Szczepankiewicz1, M. Sassek1, M.Z. Strowski2
1Department of Animal Physiology and Biochemistry, Poznań University of Life 
Science 
2Department of Hepatology and Gastroenterology and Interdisciplinary Centre 
of Metabolism: Endocrinology, Diabetes and Metabolism, Charité-University 
Medicine Berlin
The neuropeptide orexin stimulates food intake and energy ex-
penditure by acting on two different receptor isoforms OXR1 and 
OXR2. Orexin exists in two isoforms, both of which bind to OXR1 
and OXR2. The studies on genetic engineered animals which lack 
or overexpress orexins or its cognate receptors revealed that orex-
in may play a role in controlling glucose homeostasis and body 
weight changes. Observational studies in narcoleptic humans who 
display orexin deficiency also indicate that orexin plays a role in the 
pathophysiology of type 2 diabetes mellitus and obesity. The results 
implicate that orexin may become an interesting therapeutic tool 
in alleviating metabolic diseases and in controlling body weight. 
Indeed, the application of exogenous orexin in narcoleptic humans 
alleviates the symptoms associated with the disease. Therefore, it is 
important to broaden our understating about the physiological role 
of orexin as well as to evaluate further its potential in the context of 
the pathophysiology of metabolic diseases. Our investigation focus-
es on the orexin role in the regulation of endocrine and metabolic 
functions in vivo and in vitro, as well as, on its possible involvement 
in the pathophysiology of type 2 diabetes mellitus and obesity.
The usefulness of MIB1 proliferation index in 
functioning and nonfunctioning pituitary adenomas, 
especially in invasive tumors
Karolina Nowakowska1, Maria Maksymowicz2, Renata 
Jonasz2, Monika Pękul2, Wiesław Bonicki3, Jacek Kunicki3
1Department of Pathology, Children’s Hospital Medical University of Warsaw, Warsaw, 
2Department of Pathology and Laboratory Diagnostics, M. Sklodowska-Curie 
Memorial Cancer Center and Institute of Oncology, Warsaw
3Department of Neurosurgery, M. Sklodowska-Curie Memorial Cancer Center and 
Institute of Oncology, Warsaw
Introduction: Pituitary adenomas are the most common intracranial 
tumors and usually are regarded as benign. According to the 2004 
WHO classification, tumors of the anterior pituitary are divided into 
adenomas, atypical adenomas and cancers. The atypical pituitary 
adenomas are defined as pituitary adenomas with the elevated 
proliferative index (> 3%). In the last few years there have been 
reports undermining the value of assessing the proliferative index 
MIB1 as a prognostic factor in those tumors. 
The aim of this study was to determine the proliferative index MIB1 
in pituitary adenomas with particular regard to invasive adenomas. 
Material and methods: 153 cases of surgically treated pituitary 
adenomas were examined. Clinically 49 patients had hormonally 
active adenomas, and 104 patients had nonfunctioning adenomas 
(among which were both tumors: null cell adenoma and silent 
adenomas — positive by immunohistochemistry).
In all the cases anterior pituitary hormones were determined 
by immunohistochemistry and the proliferative index MIB1 was 
evaluated. All the tumors were studied by electron microscopy.
Results: Among 153 examined pituitary adenomas, 18 atypical 
tumors were found. In 47 tumors clinical invasiveness was shown, 
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among which 5 cases of atypical adenomas were found. Among 
them, 2 sparsely granulated somatotroph adenomas, 1 densely 
granulated corticotroph adenoma, 1 sparsely granulated lactotroph 
adenoma and 1 gonadotroph adenoma were diagnosed.
Conclusion: On the basis of the evaluated material we cannot con-
firm the assessment of the proliferative index MIB1 as a prognostic 
factor in invasive pituitary adenomas.
Resistin as marker of endothelial cells (HAEC) 
dysfunction under hyperglycemic stress
Ewa Ocłoń, Joanna Zubel-Łojek, Anna Latacz,  
Klaudia Pałka, Krystyna Pierzchała-Koziec
Department of Animal Physiology and Endocrinology, Faculty of Animal Sciences, 
University of Agriculture in Krakow
Introduction: Hyperglycemia is a risk factor for cardiovascular 
diseases. Resistin, a newly discovered adipocyte-derived cytokine, 
may play an important role in insulin resistance, diabetes, and 
cardiovascular disease. 
The aim of this study was to determine the effect of resistin on 
endothelial cell function in response to hyperglycemic stress. 
Furthermore, the adipokine was estimated as an indicator of en-
dothelium dysfunction.
Materials and methods: Human aortic endothelial cells (HAEC) 
were cultured in a standard medium (M 199). The experiment was 
performed two times on the forth passage of HAEC culture. The 
cultures were incubated for 48 hours in four treatment groups: 
control (5.5 mmol/L glucose), hyperglycemia (22.2 mmol/L glucose), 
resistin (500 nM) and resistin + hyperglycemia (500 nM resistin 
+ 22.2 mmol/L glucose). The activity of HAEC was evaluated by 
measurement endothelin secretion 1 and proliferation rate. 
Results: The secretion of resistin was increased by 42.1% during 
hyperglycemia (p < 0.05). Resistin caused the increase in endothelin 
1 secretion by 43.5% (p < 0.05) and the decrease of cell proliferation 
rate by 44.2% (p < 0.05).
Conclusions:
1. The activity of aortic endothelial cell negatively changed in 
response to hyperglycemic stress. 
2. Hyperglycemia increases resistin secretion which induces en-
dothelial dysfunction by reducing proliferation and increasing the 
secretion of ET-1. 
3. Resistin seems to be a potential prognostic marker for endothe-
lium dysfunction under hyperglycemic stress.
Supported by DS 3243/KEiEZ/
The role of opioid peptides in the modulation  
of gonadotropin and prolactin secretion from  
the anterior pituitary of cyclic gilts — the in vitro studies
Stanisław Okrasa1, Bartosz Wylot1, 2, Kinga Tworus1, 
Mariusz Dziekoński1
1Department of Animal Physiology, Faculty of Biology and Biotechnology, Univer-
sity of Warmia and Mazury, Olsztyn, Poland
2Department of Cell Biology, Nencki Institute of Experimental Biology, Warsaw, 
Poland
Endogenous opioid peptides (EOP) derive from high-molecular 
opioid precursors: proopiomelanocortin (POMC), proenkephalin 
(PENK), prodynorphin (PDYN), and act through three major types 
of opioid receptors: mu, delta and kappa. They are involved in the 
regulation of reproductive processes in females, participating in 
the control of gonadotropin and prolactin secretion. These effects 
might be implemented through their action at the hypothalamic and 
pituitary levels. Genes cording for opioid precursors and receptors 
are expressed in the anterior pituitary. This presentation involves 
data on: 1) the effects of potential gonadotropin (GnRH, estradiol, 
progesterone, inhibin and activin) and prolactin (TRH, dopamine, 
oxytocin, kisspeptin and PGF2α or PGE2) secretagogues on the 
gene expression of opioid precursors and receptors in vitro in the 
anterior pituitary cells of gilts in the luteal and follicular phase 
of the estrous cycle as well as 2) the influence of opioid receptor 
agonists (mu, delta and kappa) on the basal and GnRH-stimulated 
gonadotropin secretion (LH and FSH), and also the basal and in 
the presence of dopamine or TRH prolactin secretion by these 
cells. The presented data have confirmed the variable pituitary 
expression of genes coding for opioid precursors and receptors in 
response to tested factors. Moreover, the inhibitory effects of kappa 
and delta opioid receptor activation on the LH and FSH secretion 
in vitro by porcine pituitary cells were noted. In turn, the influ-
ence of opioid receptor agonists on prolactin secretion was more 
variable and dependent on the stage of the estrous cycle. During 
the luteal phase, its secretion was reduced after activation of mu, 
delta and kappa opioid receptors under all tested conditions. In the 
early follicular phase, the activation of mu, delta and kappa opioid 
receptors increased prolactin secretion under basal conditions, and 
delta receptor — in the presence of TRH, whereas the stimulation 
of mu and kappa receptors inhibited its secretion in the presence 
of dopamine. In the late follicular phase, kappa receptor agonist 
stimulated prolactin secretion under all tested conditions. In turn, 
the activation of mu and delta receptors increased its secretion under 
basal conditions and in the presence of dopamine, but decreased 
— in the presence of TRH.
The presented data indicate the participation of endogenous opioid 
peptides in the modulation of gonadotropin (mainly dynorphins 
and enkephalins) and prolactin (all families of EOP) secretion at 
the pituitary level in gilts during the estrous cycle.
Phoenixin — a new player in the gonadal axis
Artur Pałasz1, Ewa Rojczyk-Gołębiewska1,  
Rafał Skowronek2
1Department of Histology, Chair of Histology and Embryology, Medical Universi-
ty of Silesia in Katowice
2Department of Forensic Medicine and Forensic Toxicology, Medical University of 
Silesia in Katowice
Introduction: The dynamic development of biotechnology results 
in the discovery and description of new neuropeptides, localized in 
different areas of the brain which have a brought, multidirectional 
spectrum of activities performed at the level of different neuronal 
pathways.
Aim of the study: 1) The review of literature concerning with 
newly-discovered neuropeptide — phoenixin (PNX) and 2) the as-
sessment of its distribution in hypothalamic structures of adult rats.
Material and methods: 1) The search of available databases for 
articles about PNX; 2) evaluation of the distribution of PNX in 
hypothalamic structures of adult Sprague-Dawley (SD) rats with 
immunohistochemistry (IHC) and immunofluorescence (IFC), using 
the original antibody from Phoenix Pharmaceuticals.
Results: 1) We found only 2 original papers and one proceeding; 
2) we confirmed the presence of PNX in various structures of the 
hypothalamus of SD rats, both by IHC and IFC.
Conclusions: PNX is a newly-discovered and still extremely poorly 
known neuropeptide, representing a unique class of hypothalamic 
regulatory factors. So far we know only that it regulates the secre-
tion of pituitary gonadotropins by modulating the expression of 
the receptor for gonadotropin-releasing hormone (GnRH-R). An 
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initial study suggests that PNX sensitizes the pituitary to the action 
of releasing factors, rather than directly stimulates the exocytosis of 
secretory vesicles to pituitary endocrine cells. Immunohistochemical 
studies revealed PNX immunoreactivity in the rat hypothalamus, 
superficial dorsal horn, spinal trigeminal tract, nucleus of the 
solitary tract; and in the population of dorsal root, trigeminal and 
nodose ganglion cells. It was also observed that exogenously admin-
istered PNX may preferentially suppress visceral pain as opposed to 
thermal pain. Recent reports suggest that the mechanism of signal 
transduction activated by PNX is MAPK/ERK pathway.
„Clinically” non-functioning pituitary adenomas 
(CNFPA)-heterogeneous group of pituitary tumors.  
Is their hormonal phenotype clinically relevant?
Marek Pawlikowski
Department of Immunoendocrinology, Chair of Endocrinology, Medical Univer-
sity of Łódź
Introduction: Pituitary adenomas, recognized before surgery as 
hormonally non-functioning, in great majority reveal the expres-
sion of pituitary hormones or their subunits in the post-operative 
immunohistochemical examination. A question arises, whether 
the hormonal phenotype recognized by immunohistochemistry is 
connected with their clinical outcome.
Material and methods: One hundred seventy six surgically re-
moved pituitary adenomas were examined. Eighty nine of them 
did not exhibit detectable hormonal activity before surgery („clini-
cally” non-functioning pituitary adenomas, CNFPA). In all samples 
immunohistochemical examination of pituitary hormones or their 
subunits was performed. A part of tumors were also examined with 
antibodies against Ki67 and prothymosin alpha (PTalfa).
Results: Majority of CNFPA (67.4%) expressed gonadotropins or their 
free subunits. Other hormones were detected as follows: GH — 45.9%; 
ACTH — 31.7%; PRL — 22.5%. Only two tumors expressed TSH. The 
hormonal phenotype of CNFPA seems to be connected with their 
recurrence rate. The recurrence rate is the highest in “pure” ” gon-
adotropinomas (33.3%) and „silent” corticotropinomas (31.5%). The 
medium frequency concerns the „silent” prolactinomas (20%), and 
the lowest the „silent” somatotropinomas (4.8%). Almost all CNFPA 
are invasive tumors and have high Ki67 index (6.4 ± 2.3%). Ki67 index 
does not differ in silent” somatotropinomas in comparison with active 
acromegaly, but is significantly higher in „silent” corticotropinomas vs. 
Cushing’s disease (4.8 ± 2.1 vs. 1.9 ± 0.65 %). ProTα index is higher 
in CNFPA in comparison to any type of functioning adenomas. The 
ProTα-positive nuclei are more abundant in “silent” corticotropinomas 
than in corticotropinomas manifesting with Cushing’s disease (19.4 
± 6.6% vs. 2.2 ± 0.6%). Similarly, “silent somatotropinomas” reveal 
a higher ProTα index as compared with acromegaly (32.8 ± 9.9% vs. 
16.7 ± 7.7% respectively). 
Conclusions: The data presented above indicate that the hormonal 
phenotype is important for the outcome of the non-functioning 
pituitary tumor. 
Central and peripheral responses of sympathetic 
nervous system to hand grip maneuver stress 
(HGME)
Krystyna Pierzchała-Koziec1, Michał Labus2,  
Michał Furdal2, Lesław Szydłowski3, Sebastian Stec4, Ewa 
Ocłoń1, Joanna Zubel1, Anna Latacz1 
1Department of Animal Physiology and Endocrinology, University of Agriculture, 
Krakow
2The Regional Specialist Hospital in Wrocław, R&D Centre, Wrocław
3Clinic of Children Cardiology, Silesian Medical University, Katowice, 4Clinic of 
Cardiology, Centre of Postgraduate Medical Education, Warsaw 
Introduction: The sympathetic nervous system responds to stress 
by releasing catecholamines, mainly adrenaline and noradrena-
line, from the central and peripheral nervous systems. Hand grip 
maneuver (HGME) test is used for the diagnosis of arrhythmia and 
the localization of ablation place. The activity of the sympathetic 
nervous system may affect the electrophysiological properties of 
the atrioventricular nodus and cause problems for the ablation 
procedure.
The aim of the study was to estimate the response of the sympathetic 
nervous system to HGME measured by cerebral and peripheral 
circulation catecholamines.
Material and methods: Hand grip maneuver (30-50% max) was 
applied to patients prepared to the ablation procedure. Blood 
was taken simultaneously from the internal jugular vein (I), the 
coronary sinus (II), the femoral vein (III) and the femoral artery 
(IV) at 5 and 10 min of calm lying, one min of stress and 2 and 3 
min after HGME had been finished. Plasma catecholamines levels 
were estimated by RIA method.
Results: HGME increased adrenaline levels in the blood taken 
from internal the jugular vein and the coronary sinus (by 38 and 
34% respectively). Unexpectedly, adrenaline levels in the blood 
from the femoral vein and the artery were decreased (by 36 and 
40%, respectively). Stress HGME increased noradrenaline levels 
in the blood taken from the internal jugular vein (by 49%) and the 
coronary sinus (by 28%). Simultaneously, noradrenaline levels were 
decreased in the coronary sinus blood (by 15%, delayed response) 
and the quick fall (after 1min of stress) of noradrenaline level was 
observed in the blood from the femoral artery. It must be pointed 
out that noradrenaline levels in the blood taken from all intakes 
were higher at 10 min of calm lying.
Conclusion: The stress responses of the sympathetic nervous 
system measured by adrenaline and noradrenaline levels depend 
on a blood drawing place.
Supported by: DS 3243/KFiEZ
Stress and pain coping strategies versus the intensity 
of premenstrual syndrome symptoms
Leszek Putyński1, Mariusz Paciorek2
1Zakład Psychopatologii i Psychologii Klinicznej, Instytut Psychologii UŁ, Łódź
2Poradnia „K” SPZOZ, Szczerców
Introduction: Premenstrual Syndrome (PMS) is a condition char-
acterised by a variety of psychical and somatic symptoms which 
occur before the menstrual period and cease after the arrival of the 
period. Hormonal disturbances are often given as the major cause of 
PMS. The role of psychological influences in the aetiology, process 
and treatment of PMS is often forgotten or ignored.
The aim of the present study was the analysis of the influence of 
stress and pain coping strategies on the intensity of emotional and 
somatic symptoms in PMS period.
Material and methods: The research was conducted in a group of 50 
women aged 20 – 35 years. The self developed inventory (IONP) was 
used to evaluate the intensity of PMS symptoms. The mini-COPE 
questionnaire was applied to detect stress coping strategies. Pain 
coping strategies were assessed using CSQ questionnaire.
Results: The results revealed the significant correlations between 
the level of PMS symptomatology and stress and pain coping strate-
gies. The women with the higher level of emotional PMS symptoms 
such as dysphoria and depression manifest more maladaptive stress 
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coping strategies than the women with the higher level of somatic 
symptoms such as pain and vasomotor symptoms. The women 
who revealed the higher level of PMS symptoms are likely to use 
filed pain coping strategies.
Conclusions: The results suggest that stress coping strategies and 
pain coping strategies are the most important psychological factors 
influencing the intensity of PMS symptoms.
Various medical treatment strategies for PMS may be the reinforce-
ment to psychological treatment. The psychotherapy may help 
women develop appropriate ways to cope with frustrations and 
discomfort of daily life in PMS time.
Melatonin mt1 receptor is involved in melatonin- 
-dependent inhibition of forskolin-stimulated 
vasopressin secretion from the rat hypothalamo- 
-neurohypophysial system in vitro
Magdalena Roszczyk, Marlena Juszczak
Department of Pathophysiology and Experimental Neuroendocrinology, Medical 
University of Lodz, Poland
Introduction: Previous in vitro studies have shown that melatonin 
(MT), at a concentration of 10–7 M, significantly inhibits forsko-
lin-stimulated vasopressin (AVP) release. The aim of the present 
investigation was, therefore, to study the effect of melatonin 
membrane receptors antagonists, i.e. luzindole (a non-selective 
antagonist of MT1 and MT2 receptors) and 4-phenyl-2-propiona-
midotetralin (4-P-PDOT — a selective antagonist of MT2 receptor), 
on MT-dependent inhibition of forskolin-stimulated AVP secretion 
from the rat hypothalamo-neurohypophysial (H-N) system in vitro.
Material and methods: Male rats served as donors of the H-N 
explants which were placed in 1 mL of Krebs-Ringer fluid (KRF) 
heated to 37oC. The H-N explants were first preincubated (for 30 
min) in KRF containing DMSO (antagonists solvent) or luzindole, or 
4-P-PDOT and next they were incubated successively in: 1 — normal 
KRF {fluid B1}, 2 — the incubation fluid as B1 enriched with MT 
(10–7 M) and/or forskolin (10–5 M), or their vehicles {fluid B2}. After 
20 min incubation in each medium (B1 and B2), they were collected 
and immediately frozen before AVP estimation by the RIA.
Results: Forskolin significantly stimulated AVP release from isolated 
H-N system which was inhibited by MT when the explants were prein-
cubated in DMSO or 4-P-PDOT. The preincubation of the explants with 
luzindole significantly suppressed the MT-dependent effects in vitro.
Conclusion: The present results demonstrate that the inhibitory 
influence of MT on cAMP-dependent activation of AVP-ergic 
neurons in the rat is mediated through membrane MT1 receptor.
This study was supported by Medical University of Lodz (grant No 
502-03/6-103-01/502-64-013).
Current methods of gene expression microarrays 
analysis for genes identification
Marcin Ruciński, Marcin Trejter, Anna Hochół-Molenda, 
Karol Jopek, Marta Szyszka, Marianna Tyczewska,  
Ludwik K. Malendowicz
Department of Histology and Embryology, Poznan University of Medical Sciences
Gene expression microarrays constitute a popular tool for the de-
termination of expression profile for multiple genes simultaneously. 
This method is based on the hybridization of labeled target genetic 
materials to probes, fixed on a solid surface. However, the large 
number of identified genes requires special analytical tools, some 
of them will be presented.
In this review, we present the overview of some methods of microar-
ray data analysis of gene expression in rat adrenal glands under 
various experimental conditions (enucleation-induced adrenal 
regeneration, rat adrenal primary cell culture, chronic and acute 
ACTH administration). All the experiments were performed by Rat 
Gene 2.1 ST Array from Affymetrix.
The values of the signal intensity of individual probes in relation to 
their position on microarray were saved as files with CEL extension. 
Most of the presented results were obtained by Bioconductor pack-
age, which is a component of R programing language. The first step 
of the microarray analysis is the general determination of expression 
changes in experimental groups. Usually differentially expressed 
genes were selected by differences in their mean expression levels 
more than two fold (fold2) and p < 0.05. General expression profile 
may be shown as a scatter plot or a volcano plot. These graphs 
present the normalized mean values of the log signal intensity 
from each of the analyzed genes. Another valuable type of graph is 
a Venn diagram. This plot is particularly useful in the studies with 
more than two experimental groups. Such graphs clearly show 
how many genes are regulated in the same way between multiple 
groups and also demonstrate how many genes are specific only to 
one particular group. The hierarchical clustering with a heat map 
graph is another approach that allows determining groups of genes 
whose expression is regulated in a similar manner. Another type 
of analysis utilizes genes annotation tags stored in Gene Ontology 
Database (GO). By GeneAnswers package and online Database for 
Annotation, Visualization and Integrated Discovery (DAVID). Few 
functional groups of genes were obtained. The final step of the mi-
croarray data analysis is the validation of obtained results. Usually 
only few of the most interesting genes are selected for validation. 
The validation of the results may be performed on mRNA level 
(QPCR) as well as on a protein level. 
This study was supported by a grant 2013/11/B/NZ4/04746 from 
National Science Centre in Poland.
Prenatal stress (PNS) and programming  
of the hypothalamo-pituitary-adrenal (HPA) axis  
— mechanisms and consequences
John A. Russell1, Paula J. Brunton2
1Centre for Integrative Physiology, College of Medicine and Veterinary Medicine, 
University of Edinburgh, United Kingdom
2Division of Neurobiology, The Roslin Institute and Royal (Dick) School  
of Veterinary Studies 
Introduction: During pregnancy stress responses of the HPA axis 
and adrenal medulla are attenuated. In pregnancy the high levels 
of allopregnanolone (AP), a neurosteroid progesterone metab-
olite, inhibit HPA stress responses [1]. Nonetheless, social stress 
in pregnancy adversely programmes offspring behaviours and 
physiological processes [2].
Aim of the study: To establish whether disrupted neurosteroid 
mechanisms underlie the programmed phenotype in PNS offspring.
Material and method: Pregnant Sprague-Dawley rats were stressed 
in the last few days of pregnancy by exposure to an aggressive 
lactating rat. Anxious behaviour of adult offspring was tested on 
the elevated plus maze and underlying changes in corticotropin 
releasing hormone (CRH) and CRH receptor (CRHR) gene expres-
sion in amygdala measured by in situ hybridisation (also in PNS 
pigs [4]; metabolic function was assessed by glucose tolerance tests 
and RT-PCR for a panel of enzymes in liver and fat [3]. HPA axis 
responses to interleukin-1β (IL-1β) were measured as ACTH and 
corticosterone secretion, and as hypothalamic CRH gene activation; 
neurosteroid deficiency was tested by pre-treating with AP (females) 
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or androstanediol (AS; males), and by assessing mRNA expression of 
5α-reductase (5αR; rate-limiting synthesising enzyme), and estradiol 
receptorβ (ERβ; AS target) in brain regions; a viral vector was used 
to up-regulate 5αR mRNA in the brainstem.
Result: PNS male rats, and PNS female pigs were more anxious, 
with increased CRH and CRHR1:2 expression in the amygdala. PNS 
rats had enhanced HPA stress responses, and adversely modified 
metabolism. Exaggerated HPA axis stress responses were nor-
malised by neurosteroid and by up-regulating 5α-R gene expression 
in the brainstem (females). PNS males had reduced ERβ mRNA 
expression in brain regions regulating the HPA axis.
Conclusions: PNS has widespread adverse, sex-dependent, ef-
fects on offspring: deficient neurosteroid production/action is an 
important factor.
Supported by: Biotechnology and Biological Sciences Research 
Council; British Council; Polish School of Medicine Memorial Fund.
Access of molecules from the periphery to the brain: 
barriers and gates of the hypothalamus
Janina Skipor
Department of Local Physiological Regulations, Institute of Animal Reproduction 
and Food Research of Polish Academy of Sciences, Olsztyn, Poland
The access of circulating factors to the brain is regulated by brain 
barriers: 1) the blood-brain barrier located in the endothelium of 
brain microvessels, 2) the blood-cerebrospinal fluid (CSF) barrier 
that consists of two main anatomical components, the internally 
situated epithelial cells of the choroid plexus and the externally 
located arachnoid membrane and 3) the CSF-brain barrier located 
in specialized ependymal cells lining the third ventricle — the 
tanycytes. Therefore, circumventricular organs (CVO) located in 
certain regions of the ventricular system of the brain play an im-
portant role in blood–brain communication. The blood-brain tissue 
exchange of molecules in CVO is enabled by the leaky endothelium, 
however, CVO are not a path across the blood-brain barrier. They 
are separated from the brain by an external glial barrier and from 
the CSF by a barrier at the ependyma. Fenestrated endothelial cells 
of median eminence (ME) together with ME and arcuate hypothala-
mus tanycytes (β2 and β1, respectively) constitute a highly sensitive 
“supply chain” for the distribution of blood-born metabolic signals. 
Leptin-mediated activation of hypothalamic neurons in the medio-
basal hypothalamus seems to require a leptin receptor signaling in 
tanycytes and a passage of leptin to the CSF. The access of molecules 
to the hypothalamus is also modulated by the level of glucose that 
can be detected by tanycytes. The decrease in blood glucose levels 
during fasting alters the structural organization of blood-brain 
barrier in the area of the arcuate hypothalamus throughout the 
mechanism that requires the expression of vascular endothelial 
growth factor (VEGF) in tanycytes. The expression of several genes 
linked to body weight and energy balance has been demonstrated 
in tanycytes, wherein the expression of certain genes is regulated 
by food restriction and day length.
Comparison of the influence of sodium valproate 
(VPA) and nifedipine (NIF) on LH release stimulated 
by GnRH and Bay K 8644 from rat anterior pituitary 
cells culture in vitro
Justyna Skrzypska1, Anna Litwiniuk1, Malgorzata Kalisz1, 
Ewa Wolinska-Witort1, Lidia Martynska1, Magdalena 
Chmielowska1, Alina Gajewska2,  
Elzbieta Wasilewska-Dziubinska1
1Department of Clinical Neuroendocrinology, Centre of Postgraduate Medical 
Education
2Department of Neuroendocrinology, The Kielanowski Institute of Animal Physio-
logy and Nutrition Polish Academy of Sciences
Introduction: Previously we reported that VPA suppressed only 
GnRH and KCl stimulated but not basal LH secretion from rat 
primary anterior pituitary cells culture. Although the mechanism 
involved in mediating VPA effects in the pituitary gland is not well 
recognized, its potential impact on intracellular calcium metabolism 
cannot be excluded. It seems that VPA may act in a similar manner 
as dihydropyridine calcium channel antagonists because NIF and 
nitrendipine inhibited GnRH stimulated LH secretion from rat 
anterior pituitary cells and did not alter basal LH release in vitro. 
It was also stated that nitrendipine blocked the potentiation of 
GnRH- induced LH secretion by calcium channel agonist Bay K 
8644 (BK 8644). If VPA acts in a similar manner as nitrendipine it 
may also suppress the ability of BK 8644 to potentiate LH responses 
to submaximal doses of GnRH.
The aim of the study was to compare the influence of VPA and 
NIF on the potentiation of GnRH and KCl induced LH secretion 
by BK 8644.
Material and methods: The primary pituitary cells culture was 
incubated 3 h with: GnRH 1 nM, GnRH 1 nM + BK 8644 1 µM, 
GnRH 1 nM + BK 8644 1 µM + VPA 10 µM, GnRH 10 nM, GnRH 10 
nM + BK 8644 , GnRH 10 nM + BK 8644 1 µM + VPA 10 µM, GnRH 
10 nM + BAY 10 µM + NIF 1 µM, GnRH 10 nM + BK 8644 1 µM + 
NIF 10 µM, KCl 30 mM, KCl 30 mM + BK 8644 1 µM, KCl 30 mM + 
BK 8644 1 µM + VPA 10 µM, KCl 30 mM+ BK 8644 1 µM + NIF 10 
µM. Medium rLH concentration were determined by RIA method. 
Results: Contrary to NIF the administration of VPA did not sup-
press the potentiation by BK 8644 of GnRH– and KCl–stimulated 
LH secretion from the rat anterior pituitary cell culture.
Conclusion: The mechanism of the inhibition by VPA stimulated 
by GnRH and KCl secretion of LH from the anterior pituitary cells 
is different from the mechanism action of NIF. 
This study was supported by CMKP grants No 506-1-31-01-13 and 
506-1-31-01-14.
Lymphocitic hypophysitis — case study
Dorota Szyska-Skrobot, Aldona Kowalska
Clinical Endocrinology and Department of Nuclear Medicine Holycross Cancer 
Center, Kielce, Poland
Introduction: Lymphocitic hypophysitis is numbered among au-
toimmune diseases with female predisposition.
Aim of the study: The presentation of the case of a female patient 
in whom the symptoms of diabetes insipidus appeared as the first 
and only manifestation of lymphocytic hypophysitis. 
Case description: A 26-year-old woman was admitted to hospital 
to have the function of the pituitary assessed. In an interview a few 
months earlier she had reported excessive thirst, increased diuresis, 
weakness, lack of appetite, weight loss. She was hospitalized in 
a local hospital, where she was diagnosed with diabetes insipidus 
and where the treatment with Adiuretin was applied. In the per-
formed MR, the pituitary stalk thickened to 5.5 mm was described 
(n. to 3.5 mm), undergoing strong contrast enhancement which 
might represent inflammatory infiltration as well as decreased 
signal from the neural part of the pituitary, characteristic of diabetes 
insipidus. On the basis of the performed hormone determination, 
the proper tropic function of the pituitary gland was found, hypo-
thyroidism in the course of Hashimoto’s disease was diagnosed 
and the differential diagnosis of hypophysitis was carried out 
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(chest X-ray and HRCT, BAL bronchoscopy, tuberculin test, ACE 
test, lumbar puncture) without finding irregularities. Based on the 
whole, lymphocytic hypophysitis was suspected and the treatment 
with Encorton was included at a dose of 60 mg per day and, while 
observing the improvement of the clinical condition, the dose of 
Adiuretin was reduced. In an imaging examination there was the 
normalization of the pituitary gland, and after a few years, the 
features of empty sella partially syndrome. The patient remains in 
observation, she takes Minirin and thyroxine.
Conclusions: Although lymphocytic hypophysitis is a rare dis-
ease, because of its potential life-threatening property it should be 
considered, particularly in women of child bearing age with the 
symptoms of hypopituitarism, diabetes insipidus and/or headache 
and disorders of the visual field in conjunction with the abnormal 
image of the gland in MR examination.
Integration of robotized radiotherapy in treatment  
of pituitary tumors
Rafał Tarnawski
III Clinic of Radiotherapy and Chemotherapy, Maria Skłodowska-Curie Memorial 
Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
Radiotherapy has a long history of use in the treatment of pituitary 
tumors. Old irradiation techniques resulted in the relatively high 
incidence of side effects due to the high volume of irradiated critical 
structures. The development of new techniques, including Image 
Quided Radiotherapy (IGRT) and Intensity Modulated Radio-
therapy (IMRT), resulted in the tremendous increase of treatment 
precision. Several clinical cases of pituitary tumors treated with 
robotized radiotherapy will be discussed.
The role of IL-1β in the regulation of hypothalamic-
pituitary-gonadal axis in ewe during immunological 
stress — the influence of central anti IL-1β antibody 
and IL-1R antagonist injection on the GnRH/LH 
secretion
Dorota Tomaszewska-Zaremba, Andrzej Przemysław Herman, 
Karolina Król, Karolina Haziak
The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of 
Sciences, Jabłonna, Poland
Introduction: Bacterial or viral infections have an inhibitory effect on 
female reproduction influencing the hypothalamic-pituitary-gonadal 
axis activity. Interleukin-1β (IL-1β) plays the main role in this process.
The aim of the study was to investigate the effect of intracere-
broventricular (icv) administration of anti-IL-1β antibody and IL-1R 
antagonist during immune stress induced by the intravenous (iv) 
administration of bacterial endotoxin — LPS on GnRH/LH secretion.
Material and methods: The study was performed on 20 anestrous 
ewes divided into 4 groups: control (NaCl iv, Ringer-Locke icv), 
LPS (LPS iv, NaCl icv), anti-IL-1β (iv LPS. anti IL-1β icv), IL-1R 
antagonist (iv LPS., IL-1R antg icv). The central injections were 
given 0.5 h before iv administration of LPS/NaCl. Blood samples 
were collected every 15 min for 6 h. After 2 weeks an analogous 
experiment was conducted. The animals were euthanized 2 hours 
after the administration of LPS/NaCl. The structures of the hypo-
thalamus: the preoptic area (POA), anterior hypothalamus (AHA), 
medial basal hypothalamus (MBH), medial eminence (ME) and 
anterior pituitary (AP) were taken and the expression of GnRH and 
LHβ genes by Real Time PCR, GnRH concentration by ELISA and 
LH level in plasma by RIA were assayed.
Results: It was shown that the injection of LPS caused a significant 
reduction in mRNA level of GnRH in POA, AHA, MBH, and ME, 
and LHβ in AP, and the expression of the GnRH peptide in POA. 
The intraventricular administration of anti IL-1β antibody and IL-
1R antagonist reversed the inhibitory effect of endotoxin on GnRH 
gene expression without affecting the GnRH peptide level in all 
studied structures; the strongest effect was observed in POA and 
ME. In AP, only IL-1R antagonist reversed the suppressive effect of 
LPS on LHβ gene expression.
Conclusion: The results confirm the hypothesis that the immune 
stress induced by LPS inhibits the secretion of GnRH/LH at the CNS 
level at least in part by IL-1β.
This work was supported by the National Science Centre, grant 
NN 31151644
Germline aryl hydrocarbon receptor interacting 
protein (AIP) gene mutations in patients with 
apparently sporadic pituitary macroadenomas (PMA) 
— a pilot study
Małgorzata Trofimiuk-Müldner, Anna Skalniak,  
Jakub Piątkowski, Grzegorz Sokołowski,  
Alicja Hubalewska-Dydejczyk
Chair and Department of Endocrinology, Jagiellonian University Medical College, 
Krakow, Poland; Department of Endocrinology, University Hospital in Krakow
Introduction: Germline AIP gene mutations have been linked with 
familial isolated pituitary adenomas (FIPA) and are responsible for 
about 15–30% of such cases. The inactivating mutations of AIP have 
also been reported in seemingly sporadic pituitary adenomas (in 
about 3–4% of all cases), particularly of early onset, aggressive, and 
growth hormone secreting.
Aim of the study: to assess the frequency and type of germline 
AIP gene mutations in patients with apparently sporadic PMAs.
Material and methods: The study included 31 consecutive patients 
with pituitary macroadenoma (17 males, 14 females; median age at 
diagnosis 43 years), followed in the Outpatient Clinic of the Endocri-
nology Department, University Hospital in Krakow. 13 subjects were 
diagnosed (based on hormonal results and, if feasible, on pituitary 
tumor histopathology) with non-functioning pituitary adenoma 
(NFPA), 10 — acromegaly, 4 — prolactinoma, 2 — Cushing’s disease, 
1 — TSH-oma, and 1 with gonadotropinoma. Median tumor size 
at diagnosis was 30 mm.
DNA of all participants was isolated from whole peripheral blood. 
The 6 exons of the AIP gene were sequenced using sanger sequenc-
ing (ABI 3500). The sequences were compared to reference data at 
NCBI, accordingly: NM_003977.2 and NP_003968.2. Nucleotide 
conservativity was estimated by Phyolop. The mutation influence 
on protein was estimated by PROVEAN Protein.
Results: 2 patients (9.8%) have been suggested to harbor a germline 
missense mutation in exon 3 of the AIP gene c.[377A > T];[ = ], 
p.[Q126L]; [ = ] (patient 1 — a 53 year old female with suprasellar 
NFPA, operated due to pituitary apoplexy symptoms — harboring 
also SNP rs2276020/c.[516C > T];[ = ], p.[D172 = ]; [ = ]; patient 2 — 
a 41 year old female with 17 mm ACTH-secreting macroadenoma). 
The mutation, to our knowledge so far unreported, is localized in 
a highly conservative region of the gene and the substitution of 
Gln with Leu at codon 126, most probably leads to the abnormal 
function of AIP suppressor gene. 
Conclusions: As both mutation carriers would not be selected for AIP 
gene sequencing based on clinical features, it seems feasible to search 
for germline AIP gene mutations in every patient with PMA. The pre-
sented report is an initial one, the recruitment of patients is still pending. 
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New prognostic classification of endocrine pituitary 
tumors useful in clinical practice 
Jacqueline Trouillas
INSERM U1028; CNRS UMR5292; Université Lyon1; Centre de Pathologie Est, 
Hospices Civils de Lyon, Lyon, France
Endocrine pituitary tumors are frequently occurring intracranial 
tumors that are historically considered as benign. However, various 
pieces of clinical evidence and data obtained from recent advances 
in pathological and molecular analyses, favor their consideration as 
more than an endocrinological disease despite the low incidence 
of metastasis. These tumors are currently classified by histological, 
immunohistochemical and numerous ultrastructural characteristics, 
without prognostic clinical correlations.
Recently, we validated a new prognostic clinicopathological clas-
sification of these pituitary tumors by a retrospective multicentric 
case-control study comprised 410 patients who had surgery for 
a pituitary tumor with long-term follow-up. Using pituitary magnet-
ic resonance imaging for diagnosis of cavernous or sphenoid sinus 
invasion, immunohistochemistry, markers of the cell cycle (Ki-67, 
mitosis) and p53, the tumors were classified according to size (micro, 
macro and giant), immunohistochemical type (PRL, GH, FSH/LH, 
ACTH and TSH) and grade (grade1a: non-invasive; 1b: non-invasive 
and proliferative; 2a: invasive; 2b: invasive and proliferative; and 
3: metastatic. Analyses of disease-free and recurrence/progression 
status revealed the significant prognostic value (p < 0.001; p < 0.05) 
of age, tumor type, and grade across all tumor types and for each 
tumor type. Invasive and proliferative tumors (grade 2b) had a poor 
prognosis, with an increased probability of tumor persistence or 
progression of 25 or 12 fold respectively compared to non-invasive 
tumors (grade 1a). On the basis of six out of the eight carcinomas of 
this series being grade 2b at the first surgery, we propose that grade 
2b or aggressive-invasive tumors are actually malignant tumors 
without metastasis. Until now, metastasis is required to give the 
diagnosis of carcinoma. However, the association of the following 
pathological signs: invasion, neoangiogenesis, vascular invasion, 
abnormal mitoses, very high indices for Ki-67 (i.e. > 10%) and p53 
(i.e. > 5%), and genomic alteration (chromosome 11 deletion in PRL 
tumors), which combined might suggest malignancy. 
In addition, pathological subtypes (silent ACTH or PRL tumors in 
men) appear to pose a higher risk of recurrence and resistance to 
conventional treatments. Moreover, molecular markers (endocan, 
somatostatine receptors) should improve the characterization of 
tumor behavior and prognosis. 
This pathological information should further help the clinician 
to select patients presenting pituitary tumors with a high risk of 
recurrence or malignancy and to propose personalized therapies.
Cushing’s syndrome — diagnostic problems
Tomasz Trybek, Aldona Kowalska
Department of Endocrinology, Holycross Cancer Center, Kielce
Most cases of endogenous Cushing’s syndrome are the result of 
the presence of corticotropin secretion pituitary adenomas. The 
diagnosis of ACTH-dependent Cushing’s syndrome requires 
a differentiation between corticotropinomas and ectopic secretion 
of ACTH or CRH syndrome. There are no pathognomonic symp-
toms of diseases. It is difficult to prove the relationship between the 
tumor and the presence of sometimes increasing concentrations of 
ACTH. The location of the source of the pathological secretion of 
adrenocorticotropic hormone may be a problem with the diagnosis 
and treatment. In this paper we present two cases of patients with 
the symptoms of hypercortisolism in ectopic Cushing’s syndrome 
and describe the problems with the location of the source of ACTH 
secretion. The first case refers to a 26 year old man who had rapidly 
developed typical clinical symptoms of hypercortisolism, with deep 
hypokalemia and markedly elevated plasma levels of ACTH and 
cortisol. Diagnostic problems appeared to differentiate the causes 
of hypercortisolism. We obtained suppression to > 50% of baseline 
of urinary 17-OHCS on day 2 in high-dose (8-mg) dexamethasone 
suppression test and ACTH and cortisol response (approximately 
30%) in CRH stimulation test. Plasma ACTH levels after CRH during 
external jugular vein catheterization did not indicate ACTH source 
of pituitary secretion. MRI scans of the pituitary were correct. CT 
scan revealed the bilateral thickening of adrenal glands, but chest 
CT scans were correct initially. The octreotide scintigraphy did not 
reveal the source of ACTH. We obtained a partial but significant 
inhibition of the synthesis of cortisol after the administration of 
a somatostatin analogue. High Resolution CT of the whole body 
revealed the left lung nodule. A left thoracotomy was performed 
and a bronchial neuroendocrine tumor was diagnosed. Postopera-
tive hormonal tests and clinical improvement revealed a complete 
cure. The second case refers to a 66 year old man, also with typical 
clinical symptoms, with a deep hypokalemia and markedly elevated 
plasma levels of ACTH and cortisol. Unlike the previous patient we 
did not obtain the suppression of baseline of urinary 17-OHCS on 
day 2 in high-dose (8-mg) dexamethasone suppression test and 
lack of response ACTH and cortisol to CRH stimulation test. The 
results of the tests indicated hypercortisolism by ectopic ACTH 
secretion. CT scan revealed a tumor of the pancreas. We obtained 
the normalization of cortisol levels using somatostatin analogs. The 
patient currently has qualified for surgery. Despite the important 
progress in diagnosis, the ACTH-dependent Cushing’s syndrome 
still remains a big challenge for clinicians and each case requires 
individual approach.
The patient with prolactinoma symptoms with no 
pituitary tumor on imaging and macroprolactinemia 
(case report)
Agnieszka Walczyk, Aldona Kowalska
Department of Endocrinology, Holy Cross Cancer Centre, Kielce, Poland
The lactotroph adenoma (prolactinoma) is the most frequent pituitary 
tumor. Supranormal serum prolactin (PRL) concentrations arising 
from the autonomous secretion by tumor cells result in hypogon-
adotropic hypogonadism presented in a reproductive female with 
amenorrhoea-galactorrhoea syndrome. It is known that there is a posi-
tive correlation between elevated serum PRL levels and prolactinoma 
size but the coexistence of macroprolactinemia may interfere in 
a correct diagnostic approach. In March 2014 a 43-year-old woman 
was admitted to the Department of Endocrinology, she presented 
with secondary amenorrhoea lasting 6 months and quite severe 
spontaneous galactorrhoea with no neurological disorders. An initial 
hormonal testing showed the level of estradiol less than 10 pg/mL, 
FSH 4.46 mIU/mL, LH 3.39 mIU/mL and hyperprolactinemia: 
3858.0 mIU/L (reference range: 40-530) with no dysfunction of main-
tain tropic axes. The elevated PRL concentrations were detected 
in all consecutive measurements: 4304…3562…3710…3689 mIU/L, 
with no response in the metoclopramid-provocation test (PRL in 
60’ — 3901, in 120’ — 3430 mIU/L). Drug-induced hyperprolac-
tinemia and systemic diseases were excluded. The initial diagnosis 
of prolactinoma was established and magnetic resonance imaging 
(MRI) focused on the sellar region was performed but no pituitary 
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pathology was shown. The diagnostic process was extended and 
the detection of macroprolactin (BB-PRL) by 25% polyethylene 
glycol (PEG) precipitation method revealed the predominance of 
BB-PRL in each serum sample ranging more than 95% of assessed 
PRL complex with normal concentrations of monomeric prolactin. 
Nonetheless, a dopamine agonist — bromocriptine has been admin-
istered due to clinically symptomatic hyperprolactinemia. Currently 
we are waiting for the effects of the recommended therapy which 
will be studied during a control visit in our outpatient clinic soon. 
In the reported case the greatest challenge for an endocrinologist is 
to determine a source of clinical symptoms uniquely dependent on 
hyperprolactinemia. Despite no evidence for the presence of a pitu-
itary tumor in MR imaging we cannot exclude the possibility of the 
existence of microprolactinoma but too small for imaging MR technique. 
Additionally, macroprolactinemia may hinder to establish an appro-
priate diagnosis. Moreover, in the presented case low concentrations 
of bioactive monomeric PRL were detected so we should consider the 
presence of intermediate molecular mass prolactin complexes able to 
connect to PRL-receptors with all known biological consequences. 
Gonadotropinoma and macroprolactinemia  
in a 40-year-old woman — diagnostic pitfalls  
(case report)
Agnieszka Walczyk1, Aldona Kowalska1, Wiesław Bonicki2
1Department of Endocrinology, Holycross Cancer Centre, Kielce, Poland
2Department of Neurosurgery, Maria Sklodowska-Curie Memorial Cancer Center 
and Institute of Oncology, Warsaw, Poland
Pituitary tumors in reproductive females may cause menstrual 
disturbances. However, secondary amenorrhea is usually the 
manifestation of prolactinoma, it also may be present as a symptom 
due to the ‘mass effect’ of pituitary tumors arising from other but 
lactotroph cells. 
In December 2011 a 40-year-old woman was admitted to the Depart-
ment of Endocrinology. She presented with secondary amenorrhea 
lasting 9 months and preceded by a 3-month oligomenorrhea, a se-
vere headache lasting 3 months, anisocoria and a right eye visual 
field defect. Prior to the admission, a gynecologist consulted her 
and premature menopause was established, however, no therapy 
was administered. Physically galactorrhea was not observed. Her 
endocrine profile showed no tyreo-, cortico- and somatropic dys-
function but total prolactin (PRL) concentrations in consecutive 
measurements were elevated: 1217…1878…1696 mIU/L (reference 
range: 40-530). The testing of gonadotropic axis: supressed LH 
(< 0.1 mIU/mL) and normal value of FSH (6.54 mIU/mL) with estra-
diol 60 pg/mL. Magnetic resonance imaging (MRI) focused on the 
sellar region showed a large solid tumor (33x30x25 mm) extending 
into the suprasellar region with fields of cystic degenerations, the 
invasion of the cavernous sinus and compressing the optic chiasm. 
The initial diagnosis of prolactinoma with a possible ‘hook effect’ 
occurring in the prolactin immunoassay was established. Nonethe-
less, the diagnosis was verified due to the retesting of the original 
serum prolactin samples with a serial dilution revealing the similar 
results to the previous prolactin levels. Moreover, free PRL turned 
out to be 318 mIU/L, macroprolactin (BB-PRL) content was 67.8% 
of the total PRL concentration of 1113 mIU/L. Finally, the patient 
diagnosed of non-functioning pituitary adenoma was recommend-
ed to surgery. On 11 January 2012, she underwent endoscopic 
transsfenoidal adenomectomy with no post-operative complica-
tions. Histopathological examination revealed the gonadotropic 
pituitary adenoma: FSH (+), alfa-subunit (+/–), LH (–) PRL (–).In 
February 2012 the restoration of menstruation was achieved, the 
visual problems totally improved, whereas, a temporary headache 
is present. In the diagnostic approach of menstrual disturbances in 
women clinicians should consider gonadotropic insufficiency due to 
pituitary tumors with possible coexistent macroprolactinemia which 
may lead to misdiagnosis and difficulties to apply an appropriate 
therapeutic strategy. 
The assessment of the effect of histone deacetylases 
(HDAC) inhibitors: Trichostatin A (TSA), Scriptaid 
(SCP) and sodium valproate (VPA) on GnRH-
stimulated secretion of LH from rat anterior pituitary 
cells in primary culture
Elzbieta Wasilewska-Dziubinska1, Alina Gajewska2, 
Justyna Skrzypska1, Anna Litwiniuk1, Malgorzata Kalisz1, 
Ewa Wolinska-Witort1, Lidia Martynska1,  
Magdalena Chmielowska1
1Department of Clinical Neuroendocrinology, Centre of Postgraduate Medical 
Education
2Department of Neuroendocrinology, The Kielanowski Institute of Animal Physio-
logy and Nutrition Polish Academy of Sciences 
Introduction: Previously we reported that VPA — an antiepi-
leptic drug- suppresses only GnRH stimulated but not basal LH 
release from rat anterior pituitary cells in vitro. The mechanism 
involved in mediatory VPA effects in pituitary cells is not well 
recognized. VPA is included in the group of HDAC. Recently it 
has been found that three different HDAC inhibitors — TSA, 
SCP and VPA have similar inhibitory effects on LH–induced 
androstendione secretion by bovine theca cells and FSH — in-
duced estrogen secretion- by bovine granulosa cells. With regard 
to the mechanism through which VPA suppresses androgen 
secretion by theca cells, the findings reported by Glister et al. 
(2012) support the notion that the action of VPA was due to its 
activity as a type 1 HDAC inhibitor. In available literature the 
research concerning TSA and SCP effects on LH secretion from 
pituitary in vitro has not been found.
Aim of the study: To explore the possibility that also the suppressive 
action of VPA on GnRH stimulated secretion of LH from anterior 
pituitary cells of rat reflects its HDAC inhibiting properties, the 
aim of this study was to compare the effects of VPA with those two 
highly potent HDAC inhibitors, TSA and SCP.
Material and methods: The experiments were performed on the 
primary culture of anterior pituitary cells of the rat. The effects of 
TSA 1 µM, SCP 1 µM and VPA 1 µM and 10 µM (as a control) on 
GnRH (100 nM)-stimulated LH release from anterior pituitary cells 
were examined after 3 h of incubation. Medium LH concentrations 
were determined by RIA method.
Results: TSA and SCP as a VPA also suppressed GnRH stimulated 
LH secretion suggesting that the action of VPA reflects its HDAC 
inhibiting properties.
Conclusion: It seems that VPA inhibits GnRH dependent LH 
stimulation likely by inhibition of HDAC.
This study was supported by CMKP grants No 501-1-31-22-13 and 
501-1-31-22-14.
Galanin and galanin-like peptide participate  
in the mechanisms of vasopressin release  
from the rat hypothalamo-neurohypophysial explant 
in vitro: the role of galanin receptors
Justyna Wodowska, Joanna Ciosek
Department of Neuropeptides Research, Chair of General and Experimental Patho-
logy, Medical University of Lodz, Poland
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Introduction: Galanin (Gal) and galanin-like peptide (GALP) are 
widely distributed in the different areas of the central nervous sys-
tem where they exert their distinct biological actions. Some previous 
findings indicate the ability of Gal and GALP to alter vasopressin 
(AVP) secretion from the posterior pituitary gland. 
Aim of the study: These experiments were performed to study 
the effects of Gal and GALP on AVP release from the incubated rat 
hypothalamo-neurohypophysial explant (Hth-NH) or neurohy-
pophysis (NH) in vitro. 
Material and methods: Male adult Wistar rats as the donors of 
appropriate nervous tissues were divided into two series: series 1 
— the incubation of Hth-NH with Gal tested at the concentrations 
10–10 and 10–8 M, series 2 — the incubation with GALP (10–10 and 
10–9 M). To some incubations galantide — an antagonist of galanin 
receptors were added. After each incubation, the samples were 
stored at –25oC until AVP estimation by radioimmunoassay.
Results: Both concentrations of Gal were found to inhibit the basic 
as well as K+-stimulated AVP release separately from the NH and 
Hth-NH; galantide at a concentration of 10–10 M blocked such Gal 
action. The presence of GALP in the incubative media was the cause 
of intensified AVP release from both NH and Hth-NH. Galantide did 
not block GALP influence on AVP secretion into incubative media.
Conclusions: It may be assumed that in the rat central nervous 
system, Gal acts as an inhibitory neuromodulator for AVP release 
via its galanin receptors. On the other hand, the stimulatory effect 
of GALP on AVP release is likely to be mediated via an unidentified 
specific GALP receptor(s).
This study was supported by grant of Medical University of Lodz 
no 502-03/6-103-02/502-64-045.
Prevalence of goiter, benign and malignant tumors  
in acromegalic patients
Kosma Woliński, Adam Stangierski, Edyta Gurgul,  
Marek Ruchała
Department of Endocrinology, Metabolism and Internal Medicine
Poznan University of Medical Sciences 
Introduction: Acromegaly is a quite rare disease caused by the 
increased secretion of growth hormone. The most commonly 
observed complications of acromegaly include cardiovascular and 
respiratory system diseases and also the increased risk of benign 
and malignant tumors. 
The aim of the study was the retrospective analysis of the prevalence 
of benign and malignant neoplasms in patients with acromegaly, 
with particular emphasis on thyroid morphological changes.
Material and methods: Medical documentation of patients treated 
in one medical center from the years 2004-2013 was searched. The 
data on the prevalence of benign and malignant neoplasms were 
assessed using the latest available records of particular patients.
Results: 180 patients with acromegaly were identified (108 women, 
72 men). The mean age at the time of the last available assessment 
was 52.5 years (standard deviation 12.2, median — 54.0). 140 patients 
(77.8%) had focal lesions in thyroid, including 110 patients with 
multinodular goiter (MNG) (61.1%) or resection of MNG in the past 
medical history. Thyroid cancer was diagnosed in 11 patients (6.1%), 
including 10 papillary and one follicular thyroid cancer. Thirty-two 
patients (17.8%) had thyroid surgery or radioiodine treatment in 
the past; among the rest of the patients a mean thyroid volume was 
35.3 ± 27.3 cm3 in men (median 30.6) and 32.5 ± 29.7 in women 
(median 22.0). Among other malignancies, the most common were 
breast cancer- in 5 patients (4.6% of women with acromegaly) and 
colonic cancer- in 4 patients (2.2%).
Conclusions: Patients with acromegaly have the high risk of goiter, 
thyroid lesions and thyroid cancer, which was present in the medical 
histories of over 6% of patients. Among other malignancies, breast 
and colonic cancer were most frequent. According to our results, an 
active screening for potential malignancies should be an important 
part in the management of acromegaly.
The effect of intracerebroventricular infusions  
of obestatin on the secretory activity of luteinizing 
hormone in the pituitary in prepubertal female 
lambs (preliminary results)
Anna Wójcik-Gładysz, Alina Gajewska, Tomasz Misztal, 
Katarzyna Romanowicz, Michał Szlis, Jolanta Polkowska
Department of Endocrinology, The Kielanowski Institute of Animal Physiology 
and Nutrition, Polish Academy of Sciences, Instytucka 3, Jabłonna, Poland
Introduction: Obestatin is an anorexigenic peptide engaged in the 
integration of information about the organism nutritional status 
with the reproductive processes. Obestatin acting both at the pe-
riphery and at the central nervous system level, along with ghrelin, 
leptin and neuropeptide Y can form a neuromodulatory network 
that modulates the gonadotrophic axis activity. The mechanism of 
obestatin action on the hypothalamic-pituitary system related to 
reproduction processes is not fully elucidated, and, especially in 
ruminants, requires intensive research.
The aim of the present study was to investigate the effect of in-
tracerebroventricular (ICV) infusion of obestatin on the secretory 
activity of LH cells in the pituitary gland in prepubertal lambs.
Material and methods: Immature female lambs were randomly 
divided into two groups. One control group (vehicle infusion) and 
an experimental group (obestatin infusion). The infusions were per-
formed during three consecutive days; blood samples were collected 
during the “day 0” and “day 3” After the experiment the sheep were 
slaughtered and the brains were protected for the further analysis.
Results: In the sheep ICV infused with obestatin the decrease in 
the secretory activity of the LH cells in the pituitary gland was 
observed. This was manifested by a reduction in the amount of 
immunoreactive LH accumulated in the secretory granules of the 
pituitary cells. The mean LH plasma concentrations decreased in the 
obestatin infused animals between day 0 and day 3 of the infusions 
(p < 0.01) compared to the values noted in the standard fed group 
and this decrease is related to a lower pulse amplitude (p < 0.05). 
However, ICV administered obestatin did not cause any changes 
in the mRNA for LHβ subunit level in the gonadotrophic cells.
Conclusions: It can be suggested that obestatin takes part in the 
mechanisms linking the nutritional status of an organism with the 
reproductive function affecting the LH - producing cells secretory 
activity in the pituitary gland. 
Pituitary adenomas — pharmacological or surgical 
treatment?
Wojciech Zgliczyński1, Grzegorz Zieliński2,  
Jolanta Kunert-Radek3
1Department of Endocrinology, Medical Centre of Postgraduate Education, 
Warsaw
2Department of Neurosurgery Military Medical Institute, Warsaw, 3Clinic of 
Endocrinology Medical University of Lodz
Pituitary adenomas are benign, slowly growing neoplasms deriving 
from adenocytes of pituitary gland, presenting mostly hormonal 
activity. They consist of very diverse group of tumours localized in 
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sella turcica region that can lead not only to hyperactivity of pituitary 
(excessive secretion of PRL, GH, ACTH, TSH, gonadotropins and 
their subunits), but also to its hypoactivity. Those tumours vary in 
size, localization, as well as infiltration of surrounding structures 
and speed of growth — invasiveness. Likewise, they may differ 
from one another in expression of dopamine and somatostatin 
receptors (including all of the subtypes). Therefore all mentioned 
factors should be considered during planning treatment schedule 
side by side with precising main goal of treatment.
In case of treatment of secretory pituitary adenomas a main objec-
tive is inhibition of their hormonal activity, which in prolactinomas 
improves gonads function, in acromegaly restores expected lifespan 
as well as improves its quality, in Cushing’s disease significantly 
decreases mortality. The next aim of therapy is reduction of size of 
a tumour that normally leads to remission of neurological disorders 
and improvement of pituitary hormonal function. 
In case of prolactinomas, treatment of first choice is a use of dopa-
mine agonists. These drugs do not only block PRL secretion, but also 
result in regression of tumour, which convinces to use conservative 
treatment as the one of choice, even in patients with big tumours 
and visual field deficits. Surgical treatment should be conducted in 
patients presenting resistance to pharmacological therapy or intoler-
ating it. Women with prolactinomas that are planning a pregnancy 
should be considered individually concerning a purpose of surgery. 
Patients with acromegaly, who prognose recovery after surgery 
should be prepared preoperatively with somatostatin analogues. 
Rest of patients, including those who already underwent surgery 
without expected remission of disease should be subjected to chron-
ic treatment with long-acting analogues of somatostatin.
Treatment of Cushing’s disease, which ought to be radical thera-
py, despite constant progress in medicine is still challenging for 
endocrinologists and neurosurgeons. Surgical treatment (treat-
ment of choice) may be difficult in cases of microadenomas that 
are not previously localized in MRI (approximately 40% of cases). 
Relatively high percentage of recurrence of hypercortisolism is 
an additional problem that may appear even many years after 
effective surgery. The advancement in Cushing’s disease therapy 
includes undertaking surgical treatment (sella turcica exploration) 
in cases of hormonally confirmed disease with negative pituitary 
magnetic resonance imaging (MRI), as well as greater possibilities 
of pharmacological therapy. Among drugs presenting causal action, 
inhibiting hormonal activity of corticotroph adenomas, it is worth 
mentioning somatostatin analogue — pasireotide, being effective 
in approx. 20% of cases and dopamine agonist — cabergoline with 
its effectiveness in approx. 40% of patients.
Most of clinically non-functioning pituitary adenomas (NFPA) are 
characterised by the high density of somatostatin receptors (SSTR). 
Last data focus on the clinical trials evaluating somatostatin ana-
logues (SSA) in the treatment of NFPA, especially in the cases of 
recurrent adenomas after the incomplete neurosurgeries of invasive 
tumours. The pharmacotherapy of primary tumours is a therapeutic 
option for patients who do not agree for neurosurgery and for those 
who are disqualified from neurosurgical procedures. The effects of 
SSA treatment in primary and recurrent NFPA as well as in cases of 
coincidence of other brain tumours were discussed.
All things considered, it is worth emphasizing to remember during 
planning a treatment of pituitary tumour that its results should not 
be worse than the disease itself.
Therefore decision about a choice of proper therapy should be made 
individually depending on type of adenoma, its size and localization 
with correlation to expected respond to pharmacological treatment 
(expression of proper receptors).
Is chromogranin A a specific marker of adrenal 
chromaffin cells?
Agnieszka Ziolkowska, Anna Hochół-Molenda,  
Marcin Trejter, Paulina Grabowska, Marianna Tyczewska, 
Marcin Ruciński, Ludwik K. Malendowicz
Department of Histology and Embryology, Poznan University of Medical Sciences
Chromogranin A (CgA) is a member of granins — a protein family 
that controls the formation and secretion of hormones from granules 
in endocrine and neuroendocrine cells. Regarding adrenal gland, 
CgA is known as an important marker of tumors derived from 
chromaffin cells (pheochromocytoma). CgA is also a prohormone that 
gives rise to several bioactive peptides such as vasostatins 1 and 2, 
chromofungin, chromacin, pancreastatin, catestatin, WE14, chro-
mostatin, GE25, parastatin, and serpinin. CgA expression has been 
demonstrated also e.g. in the adenohypophysis, islets of Langer-
hans, follicular and parafollicular cells of the thyroid gland, DNES 
cells of the gastrointestinal tract and in many other endocrine cells. 
These observations led us to the precise analysis of CgA expression 
in particular components of the rat adrenal gland.
In mammals, adrenal glands are composed of a centrally placed 
medulla and peripherally situated cortex. The cortex and medulla 
arise from different germ layers, however these two components 
(with different structure and function) — even in a mature gland 
— are not strictly separated from each other. 
It has been shown using QPCR, that adrenal glands express CgA 
from the earliest stages of postnatal development. The highest 
CgA expression level was observed in neonates. The expression 
level of many bioactive peptides and neuropeptides in adrenal 
glands increases and could be related to the stress occurring 
during delivery. In the subsequent periods of ontogenesis the 
significant decrease of CgA expression was observed, followed by 
a slight increase during puberty period. The expression profile of 
CgA was similar in both sexes. CgA expression at the mRNA level 
was observed in all adrenal components, however, the expres-
sion in the cortex was several times lower than in the medulla. 
CgA expression was investigated during enucleation-induced 
adrenal regeneration. From the first day of the experiment CgA 
expression was significantly lower than in the control adrenal 
cortex, and temporarily increased on day 8.
CgA expression has been also demonstrated in rat adrenocortical 
cells, both freshly isolated as well as in primary culture. In cultured 
adrenocortical cells ACTH increases CgA expression. 
CgA expression at protein level was confirmed by immunoflu-
orescence. Using this method also a co-localization of CgA and 
steroidogenic acute regulatory protein (StAR) was demonstrated.
CgA expression in rat adrenocortical cells was significantly lower 
than in medullary chromaffin cells, but simultaneously higher 
than in the cells of other examined endocrine glands (pituitary, 
thyroid, ovary and testis). In contrast to the medulla, where CgA 
is easily detectable at protein level, in the cortical cells CgA protein 
expression is very low. The enzymatic modifications of CgA that - 
potentially - occurs in adrenocortical cells may prevent the binding 
of the antibody - used in immunohistochemical and immunofluo-
rescence method — to the native protein. It may suggest the rapid 
metabolism of CgA in steroidogenic cells and indicates a different 
function of this peptide in adrenocortical cells when compared to 
the medulla. 
This study was supported by a grant N N401 334639 from the 
Ministry of Science and Education in Poland.
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Acute and chronic inflammation modulate 
hypothalamic ghrelin secretion in piglets
Joanna Zubel-Łojek, Ewa Ocłoń, Anna Latacz,  
Klaudia Pałka, Krystyna Pierzchała-Koziec 
Department of Animal Physiology and Endocrinology, University of Agriculture, 
Krakow, Poland
Introduction: Ghrelin was primarily isolated from the stomach 
but is also distributed in the central nervous fragments. Ghrelin 
plays an important role in energy homeostasis, the control of food 
intake and immunity. There is evidence suggesting that ghrelin is 
associated with immune cells activity. 
Aim of study: The present study was performed to examine the 
effect of TNF and dexaven on the hypothalamic ghrelin secretion 
during acute and chronic inflammation.
Material and methods: The experiment was carried out on 10-week-
old piglets (n = 24). The animals (females) were kept in standard 
conditions and divided into 4 experimental groups: I — control, 
II — chronic inflammation (overweight), III — acute inflammation 
and IV — overweight with acute inflammation. The piglets from 
groups I and III were fed with commercial food, whereas the ani-
mals from groups II and IV received high-calories diet in order to 
develop overweight. For inducing acute inflammation the animals 
received a single i.p. injection of streptozotocin (100 mg/kg b.w.). 
24 hours after the injection the hypothalamus was quickly removed. 
The tissue fragments were placed in Eagle’a medium and incubate 
20 min without (basal release) or with the addition of exogenous 
TNF or dexaven (DEX). The media were directed to the estimation 
of ghrelin secretion (RIA, Millipore). 
Results: It was observed that inflammatory process (acute and 
chronic inflammation) changed in vitro ghrelin release from the 
hypothalamus. Also in vitro addition of TNF increased (84–172%), 
whereas DEX decreased (16–82%) ghrelin secretion.
Conclusions: The obtained results indicate that hypothalamic 
ghrelin secretion is modulated by the immune system activity.
Supported by: NN 311 227 138, DS 3243/KFiEZ
Survivin expression in invasive pituitary gland 
adenomas with a diameter exceeding 20 mm
Ariadna Zybek1 , Joanna Waligórska-Stachura1,  
Nadia Sawicka-Gutaj1, Mirosław Andrusiewicz2,  
Marek Ruchała1
1Department of Endocrinology, Metabolism and Internal Medicine, Poznan Uni-
versity of Medical Sciences, Poznan, Poland
2Department of Cell Biology, Poznan University of Medical Sciences, Poznan, Poland
Introduction: Survivin is a multifunctional protein and acts as the 
inhibitor of apoptosis. Its expression occurs in nearly all human 
cancers. In some tumors survivin expression correlates with the 
malignant behavior and the diminished response to cytotoxic ther-
apy. The data concerning survivin expression in invasive pituitary 
gland adenomas are contradictory.
Material and methods: Survivin expression was assessed in 
38 invasive pituitary gland adenomas (31 non-functioning tumours, 
seven somatotroph adenomas) with a diameter exceeding 20 mm, 
removed during transsphenoidal surgery. 12 control samples of the 
normal pituitary tissue were obtained post-mortem. The tumour 
size was assessed by preoperative MRI scan. The amplification of 
survivin gene using sequence specific primers and qRT-PCR method 
was performed.
Results: The mean age of patients was 54 ± 14 years. The mean 
tumour size was 33.8 mm ± 7.8 mm (Min. 20 mm, and Max. 
55 mm). Survivin expression was found in 31 out of 38 tumours and 
in ten out of 12 control samples. There was no difference between 
the level of survivin expression in the pituitary adenomas and in 
the normal pituitary tissue samples.
Conclusions: Survivin expression in invasive pituitary adenomas 
varies greatly. Our results suggest that survivin expression in 
invasive pituitary adenomas is comparable to the healthy tis-
sue. Since a considerable effort has been made in recent years 
to explore new therapeutic options based on survivin counter-
acting chemicals, its potential role in pituitary adenomas needs 
further evaluation.
